-
2
-
-
33745919520
-
Epidemiology of parkinson's disease
-
de Lau, L.M.L.; Breteler, M.M.B. Epidemiology of Parkinson's disease. Lancet Neurol., 2006, 5(6), 525-535.
-
(2006)
Lancet Neurol.
, vol.5
, Issue.6
, pp. 525-535
-
-
De Lau, L.M.L.1
Breteler, M.M.B.2
-
3
-
-
0037417254
-
Alzheimer's disease and parkinson's disease
-
Nussbaum, R.L.; Ellis, C.E. Alzheimer's disease and Parkinson's disease. N. Engl. J. Med., 2003, 348, 1356-1364.
-
(2003)
N. Engl. J. Med.
, vol.348
, pp. 1356-1364
-
-
Nussbaum, R.L.1
Ellis, C.E.2
-
4
-
-
2542596183
-
Parkinson's disease
-
Samii, A.; Nutt, J.G.; Ransom, B.R. Parkinson's disease. Lancet, 2004, 363, 1783-1793.
-
(2004)
Lancet
, vol.363
, pp. 1783-1793
-
-
Samii, A.1
Nutt, J.G.2
Ransom, B.R.3
-
5
-
-
84863402942
-
Cost of disorders of the brain in Europe 2010
-
Gustavsson, A.; Svensson, M.; Jacobi, F.; Allgulander, C.; Alonso, J.; Beghi, E.; Dodel, R.; Ekman, M.; Faravelli, C.; Fratiglioni, L.; Gannon, B.; Jones, D.H.; Jennum, P.; Jordanova, A.; Jönsson, L.; Karampampa, K.; Knapp, M.; Kobelt, G.; Kurth, T.; Lieb, R.; Linde, M.; Ljungcrantz, C.; Maercker, A.; Melin, B.; Moscarelli, M.; Musayev, A.; Norwood, F.; Preisig, M.; Pugliatti, M.; Rehm, J.; Salvador-Carulla, L.; Schlehofer, B.; Simon, R.; Steinhausen, H.-C.; Stovner, L.J.; Vallat, J.-M.; Van den Bergh, P.; van Os, J.; Vos, P.E.; Xu, W.; Wittchen, H.-U.; Jönsson, B.; Olesen, J. Cost of disorders of the brain in Europe 2010. Eur. Neuropsychopharmacol., 2012, 22(3), 237-238.
-
(2012)
Eur. Neuropsychopharmacol.
, vol.22
, Issue.3
, pp. 237-238
-
-
Gustavsson, A.1
Svensson, M.2
Jacobi, F.3
Allgulander, C.4
Alonso, J.5
Beghi, E.6
Dodel, R.7
Ekman, M.8
Faravelli, C.9
Fratiglioni, L.10
Gannon, B.11
Jones, D.H.12
Jennum, P.13
Jordanova, A.14
Jönsson, L.15
Karampampa, K.16
Knapp, M.17
Kobelt, G.18
Kurth, T.19
Lieb, R.20
Linde, M.21
Ljungcrantz, C.22
Maercker, A.23
Melin, B.24
Moscarelli, M.25
Musayev, A.26
Norwood, F.27
Preisig, M.28
Pugliatti, M.29
Rehm, J.30
Salvador-Carulla, L.31
Schlehofer, B.32
Simon, R.33
Steinhausen, H.-C.34
Stovner, L.J.35
Vallat, J.-M.36
Van Den Bergh, P.37
Van Os, J.38
Vos, P.E.39
Xu, W.40
Wittchen, H.-U.41
Jönsson, B.42
Olesen, J.43
more..
-
8
-
-
0034658015
-
Impact of Parkinson's disease and its pharmacologic treatment on quality of life and economic outcomes
-
Scheife, R.T.; Schumock, G.T.; Burstein, A.; Gottwald, M.D.; Luer, M.S. Impact of Parkinson's disease and its pharmacologic treatment on quality of life and economic outcomes. Am. J. Health Syst. Pharm., 2000, 57, 953-962.
-
(2000)
Am. J. Health Syst. Pharm.
, vol.57
, pp. 953-962
-
-
Scheife, R.T.1
Schumock, G.T.2
Burstein, A.3
Gottwald, M.D.4
Luer, M.S.5
-
10
-
-
0037675042
-
Incidence of Parkinson's disease: Variation by age, gender, and race/ethnicity
-
Van, D.E.S.K.; Tanner, C.M.; Bernstein, A.L.; Fross, R.D.; Leimpeter, A.; Bloch, D.A.; Nelson, L.M. Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. Am. J. Epidemiol., 2003, 157, 1015-1022.
-
(2003)
Am. J. Epidemiol.
, vol.157
, pp. 1015-1022
-
-
Van, D.E.S.K.1
Tanner, C.M.2
Bernstein, A.L.3
Fross, R.D.4
Leimpeter, A.5
Bloch, D.A.6
Nelson, L.M.7
-
11
-
-
35048860925
-
Management of Parkinson disease: Current treatments, recent advances, and future development
-
Lo, K.; Leung, K.; Shek, A. Management of Parkinson disease: current treatments, recent advances, and future development. Formulary, 2007, 42, 529-544.
-
(2007)
Formulary
, vol.42
, pp. 529-544
-
-
Lo, K.1
Leung, K.2
Shek, A.3
-
12
-
-
84865735047
-
Medication management of parkinson's disease: Early versus advanced stages
-
Tsai, S.-C.; Yuan, R.-Y. Medication Management of Parkinson's Disease: Early versus Advanced Stages. J. Exp. Clin. Med., 2012, 4(4), 209-214.
-
(2012)
J. Exp. Clin. Med.
, vol.4
, Issue.4
, pp. 209-214
-
-
Tsai, S.-C.1
Yuan, R.-Y.2
-
13
-
-
80053898301
-
Available and emerging treatments for parkinson's disease: A review
-
Hickey, P.; Stacy, M. Available and emerging treatments for Parkinson's disease: a review. Drug Des. Devel. Ther., 2011, 5, 241-254.
-
(2011)
Drug Des. Devel. Ther.
, vol.5
, pp. 241-254
-
-
Hickey, P.1
Stacy, M.2
-
14
-
-
84863699012
-
Emerging therapies for parkinson's disease
-
Poewe, W.; Mahlknecht, P.; Jankovic, J. Emerging therapies for Parkinson's disease. Curr. Opin. Neurol., 2012, 25, 448-459.
-
(2012)
Curr. Opin. Neurol.
, vol.25
, pp. 448-459
-
-
Poewe, W.1
Mahlknecht, P.2
Jankovic, J.3
-
15
-
-
0026005169
-
N-methyl-d-aspartate antagonists in the treatment of parkinson's disease
-
Greenamyre, J.; O'Brien, C.F. N-methyl-d-aspartate antagonists in the treatment of parkinson's disease. Arch. Neurol., 1991, 48(9), 977-981.
-
(1991)
Arch. Neurol.
, vol.48
, Issue.9
, pp. 977-981
-
-
Greenamyre, J.1
O'Brien, C.F.2
-
16
-
-
78449244955
-
Amantadine and anticholinergics
-
Dashtipour, K.; Chung, J.S.; Wu, A.D.; Lew, M.F. Amantadine and anticholinergics. Neurol. Dis. Ther., 2007, 92, 293-307.
-
(2007)
Neurol. Dis. Ther.
, vol.92
, pp. 293-307
-
-
Dashtipour, K.1
Chung, J.S.2
Wu, A.D.3
Lew, M.F.4
-
17
-
-
73449139510
-
Novel investigational adenosine A2A receptor antagonists for Parkinson's disease
-
Pinna, A. Novel investigational adenosine A2A receptor antagonists for Parkinson's disease. Expert Opin. Inv. Drug., 2009, 18(11), 1619-1631.
-
(2009)
Expert Opin. Inv. Drug.
, vol.18
, Issue.11
, pp. 1619-1631
-
-
Pinna, A.1
-
18
-
-
84859560679
-
Therapeutic potential of A2 and A3 adenosine receptor: A review of novel patented ligands
-
Federico, S.; Spalluto, G. Therapeutic potential of A2 and A3 adenosine receptor: a review of novel patented ligands. Expert Opin. Ther. Pat., 2012, 22, 369-390.
-
(2012)
Expert Opin. Ther. Pat.
, vol.22
, pp. 369-390
-
-
Federico, S.1
Spalluto, G.2
-
19
-
-
84863687148
-
A2A receptor antagonism and dyskinesia in Parkinson's disease
-
Morelli, M.; Blandini, F.; Simola, N.; Hauser, R.A. A2A receptor antagonism and dyskinesia in Parkinson's disease. Parkinson's Dis., 2012, 489853-489861.
-
(2012)
Parkinson's Dis.
, pp. 489853-489861
-
-
Morelli, M.1
Blandini, F.2
Simola, N.3
Hauser, R.A.4
-
20
-
-
80054959849
-
Adenosine A2A receptor antagonists and parkinson's disease
-
Shook, B.C.; Jackson, P.F. Adenosine A2A Receptor Antagonists and Parkinson's Disease. ACS Chem. Neurosci., 2011, 2, 555-567.
-
(2011)
ACS Chem. Neurosci.
, vol.2
, pp. 555-567
-
-
Shook, B.C.1
Jackson, P.F.2
-
21
-
-
79952918806
-
Novel therapy in Parkinson's disease: Adenosine A2A receptor antagonists
-
Szaboo, N.; Kincses, Z.T.; Veecsei, L., Novel therapy in Parkinson's disease: adenosine A2A receptor antagonists. Expert Opin. Drug Metab. Toxicol., 2011, 7, 441-455.
-
(2011)
Expert Opin Drug Metab. Toxicol.
, vol.7
, pp. 441-455
-
-
Szaboo, N.1
Kincses, Z.T.2
Veecsei, L.3
-
22
-
-
1442302324
-
Neurokinin peptides and neurokinin receptors as potential therapeutic intervention targets of basal ganglia in the prevention and treatment of Parkinson's disease
-
Chen, L.W.; Yung, K.K.L.; Chan, Y.S. Neurokinin peptides and neurokinin receptors as potential therapeutic intervention targets of basal ganglia in the prevention and treatment of Parkinson's disease. Curr. Drug Targets, 2004, 5, 197-206.
-
(2004)
Curr. Drug Targets
, vol.5
, pp. 197-206
-
-
Chen, L.W.1
Yung, K.K.L.2
Chan, Y.S.3
-
23
-
-
2942597453
-
Neurokinin B, neurotensin, and cannabinoid receptor antagonists and Parkinson disease
-
Mesnage, V.; Houeto, J.L.; Bonnet, A.M.; Clavier, I.; Arnulf, I.; Cattelin, F.; Le, F.G.; Damier, P.; Welter, M.L.; Agid, Y. Neurokinin B, neurotensin, and cannabinoid receptor antagonists and Parkinson disease. Clin. Neuropharmacol., 2004, 27, 108-110.
-
(2004)
Clin. Neuropharmacol.
, vol.27
, pp. 108-110
-
-
Mesnage, V.1
Houeto, J.L.2
Bonnet, A.M.3
Clavier, I.4
Arnulf, I.5
Cattelin, F.6
Le, F.G.7
Damier, P.8
Welter, M.L.9
Agid, Y.10
-
24
-
-
80055002811
-
Past, present and future of A2A adenosine receptor antagonists in the therapy of Parkinson's disease
-
Armentero, M.T.; Pinna, A.; Ferre, S.; Lanciego, J.L.; Mueller, C.E.; Franco, R. Past, present and future of A2A adenosine receptor antagonists in the therapy of Parkinson's disease. Pharmacol. Ther., 2011, 132, 280-299.
-
(2011)
Pharmacol. Ther.
, vol.132
, pp. 280-299
-
-
Armentero, M.T.1
Pinna, A.2
Ferre, S.3
Lanciego, J.L.4
Mueller, C.E.5
Franco, R.6
-
25
-
-
84877055074
-
Parkinson's disease: Gene therapies
-
Coune, P.G.; Schneider, B.L.; Aebischer, P. Parkinson's disease: gene therapies. Cold Spring Harb. Perspect. Med., 2012, 2, a009431.
-
(2012)
Cold Spring Harb. Perspect. Med.
, vol.2
-
-
Coune, P.G.1
Schneider, B.L.2
Aebischer, P.3
-
26
-
-
84859735330
-
Gene therapy for parkinson's disease
-
Denyer, R.; Douglas, M.R. Gene therapy for Parkinson's disease. Parkinsons Dis., 2012, 2012, 757305.
-
(2012)
Parkinsons Dis.
, vol.2012
, pp. 757305
-
-
Denyer, R.1
Douglas, M.R.2
-
27
-
-
84860213812
-
Challenges for gene therapy of CNS disorders and implications for parkinson's disease therapies
-
Broadstock, M.; Yanez-Munoz, R.J. Challenges for Gene Therapy of CNS Disorders and Implications for Parkinson's Disease Therapies. Hum. Gene Ther., 2012, 23, 340-343.
-
(2012)
Hum. Gene Ther.
, vol.23
, pp. 340-343
-
-
Broadstock, M.1
Yanez-Munoz, R.J.2
-
28
-
-
80052876242
-
The current status of gene therapy for parkinson's disease
-
Muramastsu, S.-I. The current status of gene therapy for Parkinson's disease. Ann. Neurosci., 2010, 17, 92-95.
-
(2010)
Ann. Neurosci.
, vol.17
, pp. 92-95
-
-
Muramastsu, S.-I.1
-
29
-
-
84870153310
-
Recent progress in gene therapy for parkinson's disease
-
Nakata, Y.; Yasuda, T.; Mochizuki, H. Recent progress in gene therapy for Parkinson's disease. Curr. Mol. Med., 2012, 12, 1311-1318.
-
(2012)
Curr. Mol. Med.
, vol.12
, pp. 1311-1318
-
-
Nakata, Y.1
Yasuda, T.2
Mochizuki, H.3
-
30
-
-
80054804774
-
An update on gene therapy in parkinson's disease
-
Witt, J.; Marks, W.J., Jr. An Update on Gene Therapy in Parkinson's Disease. Curr. Neurol. Neurosci. Rep., 2011, 11, 362-370.
-
(2011)
Curr. Neurol. Neurosci. Rep.
, vol.11
, pp. 362-370
-
-
Witt, J.1
Marks Jr., W.J.2
-
31
-
-
84870885663
-
AAV2-neurturin (CERE-120) for parkinson's disease
-
Hickey, P.; Stacy, M. AAV2-neurturin (CERE-120) for Parkinson's disease. Expert Opin. Biol. Ther., 2013, 13(1), 137-145.
-
(2013)
Expert Opin. Biol. Ther.
, vol.13
, Issue.1
, pp. 137-145
-
-
Hickey, P.1
Stacy, M.2
-
32
-
-
79951476995
-
Bioactivity of AAV2-neurturin gene therapy (CERE-120): Differences between Parkinson's disease and nonhuman primate brains
-
Bartus, R.T.; Herzog, C.D.; Chu, Y.; Wilson, A.; Brown, L.; Siffert, J.; Johnson, E.M., Jr.; Olanow, C.W.; Mufson, E.J.; Kordower, J.H. Bioactivity of AAV2-neurturin gene therapy (CERE-120): Differences between Parkinson's disease and nonhuman primate brains. Movement Disord., 2010, 27-36.
-
(2010)
Movement Disord.
, pp. 27-36
-
-
Bartus, R.T.1
Herzog, C.D.2
Chu, Y.3
Wilson, A.4
Brown, L.5
Siffert, J.6
Johnson Jr., E.M.7
Olanow, C.W.8
Mufson, E.J.9
Kordower, J.H.10
-
33
-
-
78349247631
-
Gene delivery of AAV2-neurturin for Parkinson's disease: A double-blind, randomised, controlled trial
-
Marks, W.J., Jr.; Bartus, R.T.; Siffert, J.; Davis, C.S.; Lozano, A.; Boulis, N.; Vitek, J.; Stacy, M.; Turner, D.; Verhagen, L.; Bakay, R.; Watts, R.; Guthrie, B.; Jankovic, J.; Simpson, R.; Tagliati, M.; Alterman, R.; Stern, M.; Baltuch, G.; Starr, P.A.; Larson, P.S.; Ostrem, J.L.; Nutt, J.; Kieburtz, K.; Kordower, J.H.; Olanow, C.W. Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol., 2010, 9, 1164-1172.
-
(2010)
Lancet Neurol.
, vol.9
, pp. 1164-1172
-
-
Marks Jr., W.J.1
Bartus, R.T.2
Siffert, J.3
Davis, C.S.4
Lozano, A.5
Boulis, N.6
Vitek, J.7
Stacy, M.8
Turner, D.9
Verhagen, L.10
Bakay, R.11
Watts, R.12
Guthrie, B.13
Jankovic, J.14
Simpson, R.15
Tagliati, M.16
Alterman, R.17
Stern, M.18
Baltuch, G.19
Starr, P.A.20
Larson, P.S.21
Ostrem, J.L.22
Nutt, J.23
Kieburtz, K.24
Kordower, J.H.25
Olanow, C.W.26
more..
-
34
-
-
41949110690
-
Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: An open-label, phase i trial
-
Marks, W.J., Jr.; Ostrem, J.L.; Verhagen, L.; Starr, P.A.; Larson, P.S.; Bakay, R.A.; Taylor, R.; Cahn-Weiner, D.A.; Stoessl, A.J.; Olanow, C.W.; Bartus, R.T. Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial. Lancet Neurol., 2008, 7, 400-408.
-
(2008)
Lancet Neurol.
, vol.7
, pp. 400-408
-
-
Marks Jr., W.J.1
Ostrem, J.L.2
Verhagen, L.3
Starr, P.A.4
Larson, P.S.5
Bakay, R.A.6
Taylor, R.7
Cahn-Weiner, D.A.8
Stoessl, A.J.9
Olanow, C.W.10
Bartus, R.T.11
-
35
-
-
23744497262
-
Enhanced expression of glutamate decarboxylase 65 improves symptoms of rat parkinsonian models
-
Lee, B.; Lee, H.; Nam, Y.R.; Oh, J.H.; Cho, Y.H.; Chang, J.W. Enhanced expression of glutamate decarboxylase 65 improves symptoms of rat parkinsonian models. Gene Ther., 2005, 12, 1215-1222.
-
(2005)
Gene Ther.
, vol.12
, pp. 1215-1222
-
-
Lee, B.1
Lee, H.2
Nam, Y.R.3
Oh, J.H.4
Cho, Y.H.5
Chang, J.W.6
-
36
-
-
79952740079
-
AAV2-GAD gene therapy for advanced Parkinson's disease: A double-blind, shamsurgery controlled, randomised trial
-
LeWitt, P.A.; Rezai, A.R.; Leehey, M.A.; Ojemann, S.G.; Flaherty, A.W.; Eskandar, E.N.; Kostyk, S.K.; Thomas, K.; Sarkar, A.; Siddiqui, M.S.; Tatter, S.B.; Schwalb, J.M.; Poston, K.L.; Henderson, J.M.; Kurlan, R.M.; Richard, I.H.; Van, M.L.; Sapan, C.V.; During, M.J.; Kaplitt, M.G.; Feigin, A. AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, shamsurgery controlled, randomised trial. Lancet Neurol., 2011, 10, 309-319.
-
(2011)
Lancet Neurol.
, vol.10
, pp. 309-319
-
-
Lewitt, P.A.1
Rezai, A.R.2
Leehey, M.A.3
Ojemann, S.G.4
Flaherty, A.W.5
Eskandar, E.N.6
Kostyk, S.K.7
Thomas, K.8
Sarkar, A.9
Siddiqui, M.S.10
Tatter, S.B.11
Schwalb, J.M.12
Poston, K.L.13
Henderson, J.M.14
Kurlan, R.M.15
Richard, I.H.16
Van, M.L.17
Sapan, C.V.18
During, M.J.19
Kaplitt, M.G.20
Feigin, A.21
more..
-
37
-
-
0037064165
-
Subthalamic GAD gene therapy in a parkinson's disease rat model
-
Luo, J.; Kaplitt, M.G.; Fitzsimons, H.L.; Zuzga, D.S.; Liu, Y.; Oshinsky, M.L.; During, M.J. Subthalamic GAD Gene Therapy in a Parkinson's Disease Rat Model. Science, 2002, 298, 425-429.
-
(2002)
Science
, vol.298
, pp. 425-429
-
-
Luo, J.1
Kaplitt, M.G.2
Fitzsimons, H.L.3
Zuzga, D.S.4
Liu, Y.5
Oshinsky, M.L.6
During, M.J.7
-
38
-
-
33847198228
-
Subthalamic glutamic acid decarboxylase gene therapy: Changes in motor function and cortical metabolism
-
Emborg, M.E.; Carbon, M.; Holden, J.E.; During, M.J.; Ma, Y.; Tang, C.; Moirano, J.; Fitzsimons, H.; Roitberg, B.Z.; Tuccar, E.; Roberts, A.; Kaplitt, M.G.; Eidelberg, D. Subthalamic glutamic acid decarboxylase gene therapy: changes in motor function and cortical metabolism. J. Cereb. Blood Flow Metab., 2007, 27, 501-509.
-
(2007)
J. Cereb. Blood Flow Metab.
, vol.27
, pp. 501-509
-
-
Emborg, M.E.1
Carbon, M.2
Holden, J.E.3
During, M.J.4
Ma, Y.5
Tang, C.6
Moirano, J.7
Fitzsimons, H.8
Roitberg, B.Z.9
Tuccar, E.10
Roberts, A.11
Kaplitt, M.G.12
Eidelberg, D.13
-
39
-
-
34250355956
-
Genetics of Parkinson's disease and parkinsonism
-
Douglas, M.R.; Lewthwaite, A.J.; Nicholl, D.J. Genetics of Parkinson's disease and parkinsonism. Expert Rev. Neurother., 2007, 7, 657-666.
-
(2007)
Expert Rev. Neurother.
, vol.7
, pp. 657-666
-
-
Douglas, M.R.1
Lewthwaite, A.J.2
Nicholl, D.J.3
-
40
-
-
33645139675
-
Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson's disease
-
Di, F.A.; Tassorelli, C.; De, M.M.; Chien, H.F.; Ferreira, J.; Rohe, C.F.; Riboldazzi, G.; Antonini, A.; Albani, G.; Mauro, A.; Marconi, R.; Abbruzzese, G.; Lopiano, L.; Fincati, E.; Guidi, M.; Marini, P.; Stocchi, F.; Onofrj, M.; Toni, V.; Tinazzi, M.; Fabbrini, G.; Lamberti, P.; Vanacore, N.; Meco, G.; Leitner, P.; Uitti, R.J.; Wszolek, Z.K.; Gasser, T.; Simons, E.J.; Breedveld, G.J.; Goldwurm, S.; Pezzoli, G.; Sampaio, C.; Barbosa, E.; Martignoni, E.; Oostra, B.A.; Bonifati, V. Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson's disease. Eur. J. Hum. Genet., 2006, 14, 322-331.
-
(2006)
Eur. J. Hum. Genet.
, vol.14
, pp. 322-331
-
-
Di, F.A.1
Tassorelli, C.2
De, M.M.3
Chien, H.F.4
Ferreira, J.5
Rohe, C.F.6
Riboldazzi, G.7
Antonini, A.8
Albani, G.9
Mauro, A.10
Marconi, R.11
Abbruzzese, G.12
Lopiano, L.13
Fincati, E.14
Guidi, M.15
Marini, P.16
Stocchi, F.17
Onofrj, M.18
Toni, V.19
Tinazzi, M.20
Fabbrini, G.21
Lamberti, P.22
Vanacore, N.23
Meco, G.24
Leitner, P.25
Uitti, R.J.26
Wszolek, Z.K.27
Gasser, T.28
Simons, E.J.29
Breedveld, G.J.30
Goldwurm, S.31
Pezzoli, G.32
Sampaio, C.33
Barbosa, E.34
Martignoni, E.35
Oostra, B.A.36
Bonifati, V.37
more..
-
41
-
-
28544441181
-
Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: Clinical, pathological, olfactory and functional imaging and genetic data
-
Khan, N.L.; Jain, S.; Lynch, J.M.; Pavese, N.; Abou-Sleiman, P.; Holton, J.L.; Healy, D.G.; Gilks, W.P.; Sweeney, M.G.; Ganguly, M.; Gibbons, V.; Gandhi, S.; Vaughan, J.; Eunson, L.H.; Katzenschlager, R.; Gayton, J.; Lennox, G.; Revesz, T.; Nicholl, D.; Bhatia, K.P.; Quinn, N.; Brooks, D.; Lees, A.J.; Davis, M.B.; Piccini, P.; Singleton, A.B.; Wood, N.W. Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data. Brain, 2005, 128, 2786-2796.
-
(2005)
Brain
, vol.128
, pp. 2786-2796
-
-
Khan, N.L.1
Jain, S.2
Lynch, J.M.3
Pavese, N.4
Abou-Sleiman, P.5
Holton, J.L.6
Healy, D.G.7
Gilks, W.P.8
Sweeney, M.G.9
Ganguly, M.10
Gibbons, V.11
Gandhi, S.12
Vaughan, J.13
Eunson, L.H.14
Katzenschlager, R.15
Gayton, J.16
Lennox, G.17
Revesz, T.18
Nicholl, D.19
Bhatia, K.P.20
Quinn, N.21
Brooks, D.22
Lees, A.J.23
Davis, M.B.24
Piccini, P.25
Singleton, A.B.26
Wood, N.W.27
more..
-
42
-
-
19944432606
-
Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease
-
Nichols, W.C.; Pankratz, N.; Hernandez, D.; Paisan-Ruiz, C.; Jain, S.; Halter, C.A.; Michaels, V.E.; Reed, T.; Rudolph, A.; Shults, C.W.; Singleton, A.; Foroud, T. Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease. Lancet, 2005, 365, 410-412.
-
(2005)
Lancet
, vol.365
, pp. 410-412
-
-
Nichols, W.C.1
Pankratz, N.2
Hernandez, D.3
Paisan-Ruiz, C.4
Jain, S.5
Halter, C.A.6
Michaels, V.E.7
Reed, T.8
Rudolph, A.9
Shults, C.W.10
Singleton, A.11
Foroud, T.12
-
43
-
-
20144387207
-
Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: Evidence of a common founder across European populations
-
Kachergus, J.; Mata, I.F.; Hulihan, M.; Taylor, J.P.; Lincoln, S.; Aasly, J.; Gibson, J.M.; Ross, O.A.; Lynch, T.; Wiley, J.; Payami, H.; Nutt, J.; Maraganore, D.M.; Czyzewski, K.; Styczynska, M.; Wszolek, Z.K.; Farrer, M.J.; Toft, M. Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations. Am. J. Hum. Genet., 2005, 76, 672-680.
-
(2005)
Am. J. Hum. Genet.
, vol.76
, pp. 672-680
-
-
Kachergus, J.1
Mata, I.F.2
Hulihan, M.3
Taylor, J.P.4
Lincoln, S.5
Aasly, J.6
Gibson, J.M.7
Ross, O.A.8
Lynch, T.9
Wiley, J.10
Payami, H.11
Nutt, J.12
Maraganore, D.M.13
Czyzewski, K.14
Styczynska, M.15
Wszolek, Z.K.16
Farrer, M.J.17
Toft, M.18
-
44
-
-
0034328925
-
Gene therapy: Trials and tribulations
-
Somia, N.; Verma, I.M. Gene therapy: trials and tribulations. Nat. Rev. Genet., 2000, 1, 91-99.
-
(2000)
Nat. Rev. Genet.
, vol.1
, pp. 91-99
-
-
Somia, N.1
Verma, I.M.2
-
45
-
-
79953267337
-
Jean-Martin Charcot: The father of neurology
-
Kumar, D.R.; Aslinia, F.; Yale, S.H.; Mazza, J.J. Jean-Martin Charcot: the father of neurology. Clin. Med. Res., 2011, 9, 46-49.
-
(2011)
Clin. Med. Res.
, vol.9
, pp. 46-49
-
-
Kumar, D.R.1
Aslinia, F.2
Yale, S.H.3
Mazza, J.J.4
-
46
-
-
34249750111
-
Jean-Martin Charcot (1825-1893): Pathologist who shaped modern neurology
-
Tan, S.Y.; Shigaki, D. Jean-Martin Charcot (1825-1893): pathologist who shaped modern neurology. Singapore Med. J., 2007, 48, 383-384.
-
(2007)
Singapore Med. J.
, vol.48
, pp. 383-384
-
-
Tan, S.Y.1
Shigaki, D.2
-
47
-
-
0027868194
-
Jean-Martin Charcot (1825-1893): His life and his legacy
-
Dubb, A. Jean-Martin Charcot (1825-1893): his life and his legacy. Adler. Mus. Bull., 1993, 19, 19-24.
-
(1993)
Adler. Mus. Bull.
, vol.19
, pp. 19-24
-
-
Dubb, A.1
-
48
-
-
84876058527
-
The history of Parkinson's disease: Early clinical descriptions and neurological therapies
-
Goetz, C.G., The history of Parkinson's disease: early clinical descriptions and neurological therapies. Cold Spring Harb. Perspect. Med., 2011, 1, a008862.
-
(2011)
Cold Spring Harb Perspect. Med.
, vol.1
-
-
Goetz, C.G.1
-
49
-
-
0036933810
-
Lesions as therapy: Surgical intervention in Parkinson's disease prior to L-dopa
-
Clower, W.T. Lesions as therapy: surgical intervention in Parkinson's disease prior to L-dopa. J. Hist. Neurosci., 2002, 11, 375-391.
-
(2002)
J. Hist. Neurosci.
, vol.11
, pp. 375-391
-
-
Clower, W.T.1
-
50
-
-
0023235687
-
Whatever happened to stereotactic surgery
-
Gildenberg, P.L. Whatever happened to stereotactic surgery? Neurosurgery, 1987, 20, 983-987.
-
(1987)
Neurosurgery
, vol.20
, pp. 983-987
-
-
Gildenberg, P.L.1
-
51
-
-
0031770369
-
Stereotactic surgery \-The past and the future
-
Gildenberg, P.L. Stereotactic surgery \-The past and the future. Stereotact. Funct. Neurosurg., 1998, 70, 57-70.
-
(1998)
Stereotact. Funct. Neurosurg.
, vol.70
, pp. 57-70
-
-
Gildenberg, P.L.1
-
52
-
-
0033986486
-
Stereotactic surgery: What is past is prologue
-
Kelly, P.J. Stereotactic surgery: what is past is prologue. Neurosurgery, 2000, 46, 16-27.
-
(2000)
Neurosurgery
, vol.46
, pp. 16-27
-
-
Kelly, P.J.1
-
53
-
-
0034050835
-
Thalamic, pallidal, or subthalamic surgery for Parkinson's disease
-
Krack, P.; Poepping, M.; Weinert, D.; Schrader, B.; Deuschl, G. Thalamic, pallidal, or subthalamic surgery for Parkinson's disease? J. Neurol., 2000, 247 II122-134.
-
(2000)
J. Neurol.
, vol.247
, pp. 122-134
-
-
Krack, P.1
Poepping, M.2
Weinert, D.3
Schrader, B.4
Deuschl, G.5
-
54
-
-
84906088600
-
-
Adapted from the following figure on
-
Adapted from the following figure on http://biomed.brown.edu/ Courses/BI108/BI108-2003-Groups/Deep-Brain-Stimulation/ images/brainslice1.gif.
-
-
-
-
55
-
-
67649225086
-
Deep brain stimulation-surgery for movement disorders and Parkinson's disease
-
Frost, E.A.M.; Osborn, I. Deep brain stimulation-surgery for movement disorders and Parkinson's disease. Int. Anesthesiol Clin., 2009, 47, 57-68.
-
(2009)
Int. Anesthesiol Clin.
, vol.47
, pp. 57-68
-
-
Frost, E.A.M.1
Osborn, I.2
-
56
-
-
84863409621
-
Efficacy and safety of deep brain stimulation as an adjunct to pharmacotherapy for the treatment of Parkinson disease
-
Sharma, A.; Szeto, K.; Desilets, A.R. Efficacy and safety of deep brain stimulation as an adjunct to pharmacotherapy for the treatment of Parkinson disease. Ann. Pharmacother., 2012, 46, 248-254.
-
(2012)
Ann. Pharmacother.
, vol.46
, pp. 248-254
-
-
Sharma, A.1
Szeto, K.2
Desilets, A.R.3
-
57
-
-
0036924327
-
Anonymous, Surgical treatment for Parkinson's disease: Deep brain surgery
-
Anonymous, Surgical treatment for Parkinson's disease: deep brain surgery. Movement Disord., 2002, 17, 128-147.
-
(2002)
Movement Disord.
, vol.17
, pp. 128-147
-
-
-
58
-
-
1942422564
-
Deep brain stimulation surgery for Parkinson's disease: Mechanisms and consequences
-
Lozano, A.M.; Mahant, N. Deep brain stimulation surgery for Parkinson's disease: mechanisms and consequences. Parkinsonism Relat. Disord., 2004, 10 49-57.
-
(2004)
Parkinsonism Relat. Disord.
, vol.10
, pp. 49-57
-
-
Lozano, A.M.1
Mahant, N.2
-
59
-
-
43649098436
-
Clinical cases where lesion therapy was chosen over deep brain stimulation
-
Hooper, A.K.; Okun, M.S.; Foote, K.D.; Fernandez, H.H.; Jacobson, C.; Zeilman, P.; Romrell, J.; Rodriguez, R.L. Clinical cases where lesion therapy was chosen over deep brain stimulation. Stereotact. Funct. Neurosurg., 2008, 86, 147-152.
-
(2008)
Stereotact. Funct. Neurosurg.
, vol.86
, pp. 147-152
-
-
Hooper, A.K.1
Okun, M.S.2
Foote, K.D.3
Fernandez, H.H.4
Jacobson, C.5
Zeilman, P.6
Romrell, J.7
Rodriguez, R.L.8
-
60
-
-
77950623416
-
Cell-based therapeutic approaches for Parkinson's disease: Progress and perspectives
-
Anisimov, S.V. Cell-based therapeutic approaches for Parkinson's disease: progress and perspectives. Rev. Neurosci., 2009, 20, 347-381.
-
(2009)
Rev. Neurosci.
, vol.20
, pp. 347-381
-
-
Anisimov, S.V.1
-
61
-
-
72949111183
-
Dopaminergic transplantation for parkinson's disease: Current status and future prospects
-
Olanow, C.W.; Kordower, J.H.; Lang, A.E.; Obeso, J.A. Dopaminergic transplantation for parkinson's disease: current status and future prospects. Ann. Neurol., 2009, 66, 591-596.
-
(2009)
Ann. Neurol.
, vol.66
, pp. 591-596
-
-
Olanow, C.W.1
Kordower, J.H.2
Lang, A.E.3
Obeso, J.A.4
-
62
-
-
42649086036
-
Stem cells and Parkinson's disease: Toward a treatment, not a cure
-
Svendsen, C. Stem cells and Parkinson's disease: toward a treatment, not a cure. Cell Stem Cell, 2008, 2, 412-413.
-
(2008)
Cell Stem Cell
, vol.2
, pp. 412-413
-
-
Svendsen, C.1
-
63
-
-
34248177735
-
Current advances in the treatment of parkinson's disease with stem cells
-
Trzaska, K.A.; Rameshwar, P. Current advances in the treatment of Parkinson's disease with stem cells. Curr. Neurovasc. Res., 2007, 4, 99-109.
-
(2007)
Curr. Neurovasc. Res.
, vol.4
, pp. 99-109
-
-
Trzaska, K.A.1
Rameshwar, P.2
-
66
-
-
0038249170
-
Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson's disease
-
Gill, S.S.; Patel, N.K.; Hotton, G.R.; O'Sullivan, K.; McCarter, R.; Bunnage, M.; Brooks, D.J.; Svendsen, C.N.; Heywood, P. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson's disease. Nat. Med., 2003, 9, 589-595.
-
(2003)
Nat. Med.
, vol.9
, pp. 589-595
-
-
Gill, S.S.1
Patel, N.K.2
Hotton, G.R.3
O'Sullivan, K.4
McCarter, R.5
Bunnage, M.6
Brooks, D.J.7
Svendsen, C.N.8
Heywood, P.9
-
67
-
-
33645739416
-
Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson's disease
-
Gill, S.S.; Patel, N.K.; Hotton, G.R.; O'Sullivan, K.; McCarter, R.; Bunnage, M.; Brooks, D.J.; Svendsen, C.N.; Heywood, P. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson's disease. Nat. Med., 2006, 12, 479.
-
(2006)
Nat. Med.
, vol.12
, pp. 479
-
-
Gill, S.S.1
Patel, N.K.2
Hotton, G.R.3
O'Sullivan, K.4
McCarter, R.5
Bunnage, M.6
Brooks, D.J.7
Svendsen, C.N.8
Heywood, P.9
-
68
-
-
84880357897
-
Development of M1 mACHR allosteric and bitopic ligands: Prospective therapeutics for the treatment of cognitive deficits
-
Davie, B.J.; Christopoulos, A.; Scammells, P.J. Development of M1 mAChR Allosteric and Bitopic Ligands: Prospective Therapeutics for the Treatment of Cognitive Deficits. ACS Chem. Neurosci., 2013, 4, 1026-1048.
-
(2013)
ACS Chem. Neurosci.
, vol.4
, pp. 1026-1048
-
-
Davie, B.J.1
Christopoulos, A.2
Scammells, P.J.3
-
69
-
-
18344413707
-
Anonymous, Management of Parkinson's disease: An evidencebased review
-
Anonymous, Management of Parkinson's disease: an evidencebased review. Movement Disord., 2002, 17, 1-166.
-
(2002)
Movement Disord.
, vol.17
, pp. 1-166
-
-
-
70
-
-
24144502098
-
Alternatives to levodopa in the initial treatment of early Parkinson's disease
-
Lees, A. Alternatives to levodopa in the initial treatment of early Parkinson's disease. Drugs Aging, 2005, 22, 731-740.
-
(2005)
Drugs Aging
, vol.22
, pp. 731-740
-
-
Lees, A.1
-
71
-
-
0036589897
-
Dopamine miracle: From brain homogenate to dopamine replacement
-
Hornykiewicz, O. Dopamine miracle: from brain homogenate to dopamine replacement. Movement Disord., 2002, 17, 501-508.
-
(2002)
Movement Disord.
, vol.17
, pp. 501-508
-
-
Hornykiewicz, O.1
-
72
-
-
4243605003
-
Synthesis of d,l-3,4-Dihydroxyphenylalanine
-
Funk, C. Synthesis of d,l-3,4-Dihydroxyphenylalanine. J. Chem. Soc., Trans., 1911, 99, 554-557.
-
(1911)
J. Chem. Soc., Trans.
, vol.99
, pp. 554-557
-
-
Funk, C.1
-
73
-
-
0001145589
-
Dioxyphenylalanin, eine neue aminosaeure aus vicia faba
-
Guggenheim, M. Dioxyphenylalanin, eine neue Aminosaeure aus Vicia faba. Hoppe-Seyler's Zeitschr. Physiol. Chem., 1913(88), 276-284.
-
(1913)
Hoppe-Seyler's Zeitschr. Physiol. Chem.
, Issue.88
, pp. 276-284
-
-
Guggenheim, M.1
-
74
-
-
0002595892
-
Enzymic destruction of ldihydroxyphenylalanine (dopa) by the kidney
-
Holtz, P.; Heise, R.; Ludtke, K. Enzymic destruction of ldihydroxyphenylalanine (dopa) by the kidney. Arch. Exp. Pathol. Pharmakol., 1938, 191, 87-118.
-
(1938)
Arch. Exp. Pathol. Pharmakol.
, vol.191
, pp. 87-118
-
-
Holtz, P.1
Heise, R.2
Ludtke, K.3
-
75
-
-
0000285068
-
Dopa decarboxylase
-
Holtz, P. Dopa decarboxylase. Naturwissenschaften, 1939, 27, 724-725.
-
(1939)
Naturwissenschaften
, vol.27
, pp. 724-725
-
-
Holtz, P.1
-
76
-
-
0002552282
-
The specific action of l-dopa decarboxylase
-
Blaschko, H. The specific action of l-dopa decarboxylase. J. Physiol., 1939, 96, 50-51.
-
(1939)
J. Physiol.
, vol.96
, pp. 50-51
-
-
Blaschko, H.1
-
77
-
-
0000428532
-
3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists
-
Carlsson, A.; Lindqvist, M.; Magnusson, T. 3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature, 1957, 180, 1200.
-
(1957)
Nature
, vol.180
, pp. 1200
-
-
Carlsson, A.1
Lindqvist, M.2
Magnusson, T.3
-
78
-
-
0001058813
-
Serotonin release as a mechanism of reserpine action
-
Pletscher, A.; Shore, P.A.; Brodie, B.B. Serotonin release as a mechanism of reserpine action. Science, 1955, 122, 374-375.
-
(1955)
Science
, vol.122
, pp. 374-375
-
-
Pletscher, A.1
Shore, P.A.2
Brodie, B.B.3
-
79
-
-
0000015266
-
The occurrence, distribution and physiological role of catecholamines in the nervous system
-
Carlsson, A. The occurrence, distribution and physiological role of catecholamines in the nervous system. Pharmacol. Rev., 1959, 11, 490-493.
-
(1959)
Pharmacol. Rev.
, vol.11
, pp. 490-493
-
-
Carlsson, A.1
-
80
-
-
0000424628
-
Catechol compounds in rat tissues and in brains of different animals
-
Montagu, K.A. Catechol compounds in rat tissues and in brains of different animals. Nature, 1957, 180, 244-245.
-
(1957)
Nature
, vol.180
, pp. 244-245
-
-
Montagu, K.A.1
-
81
-
-
0000275068
-
Intracellular distribution of catecholamines in the brain
-
Weil-Malherbe, H.; Bone, A.D. Intracellular distribution of catecholamines in the brain. Nature, 1957, 180, 1050-1051.
-
(1957)
Nature
, vol.180
, pp. 1050-1051
-
-
Weil-Malherbe, H.1
Bone, A.D.2
-
82
-
-
0000022434
-
Occurrence and distribution of catechol amines in brain
-
Bertler, A.; Rosengren, E. Occurrence and distribution of catechol amines in brain. Acta Physiol. Scand., 1959, 47, 350-361.
-
(1959)
Acta Physiol. Scand.
, vol.47
, pp. 350-361
-
-
Bertler, A.1
Rosengren, E.2
-
83
-
-
34250928307
-
Distribution of noradrenaline and dopamine (3-hydroxytyramine) in human brain and its relation to diseases of the extrapyramidal system
-
Ehringer, H.; Hornykiewicz, O. Distribution of noradrenaline and dopamine (3-hydroxytyramine) in human brain and its relation to diseases of the extrapyramidal system. Klin. Wochenschr., 1960, 38, 1236-1239.
-
(1960)
Klin. Wochenschr.
, vol.38
, pp. 1236-1239
-
-
Ehringer, H.1
Hornykiewicz, O.2
-
84
-
-
73049129373
-
The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia
-
Birkmayer, W.; Hornykiewicz, O. The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia. Wien Klin. Wochenschr., 1961, 73, 787-788.
-
(1961)
Wien Klin. Wochenschr.
, vol.73
, pp. 787-788
-
-
Birkmayer, W.1
Hornykiewicz, O.2
-
85
-
-
0344018017
-
The efficacy of l-dopa in Parkinson patients with and without stereotactic brain surgery
-
Umbach, W.; Baumann, D. The efficacy of l-dopa in Parkinson patients with and without stereotactic brain surgery. Arch. Psychiatr. Nervenkr., 1964, 205, 281-292.
-
(1964)
Arch. Psychiatr. Nervenkr.
, vol.205
, pp. 281-292
-
-
Umbach, W.1
Baumann, D.2
-
86
-
-
76549151865
-
Effect of L-dopa on akinesia and other extrapyramidal motor disorders
-
Hirschmann, J.; Mayer, K. Effect of L-dopa on akinesia and other extrapyramidal motor disorders. Deut. Med. Wochenschr., 1964, 89, 1877-1880.
-
(1964)
Deut. Med. Wochenschr.
, vol.89
, pp. 1877-1880
-
-
Hirschmann, J.1
Mayer, K.2
-
88
-
-
0344537380
-
Dopamine metabolism in Parkinsonism
-
Greer, M.; Williams, C.M. Dopamine metabolism in Parkinsonism. Neurology, 1963, 13, 73-76.
-
(1963)
Neurology
, vol.13
, pp. 73-76
-
-
Greer, M.1
Williams, C.M.2
-
89
-
-
0014208039
-
Aromatic amino acids and modification of parkinsonism
-
Cotzias, G.C.; Van, W.M.H.; Schiffer, L.M. Aromatic amino acids and modification of parkinsonism. N. Engl. J. Med., 1967, 276, 374-379.
-
(1967)
N. Engl. J. Med.
, vol.276
, pp. 374-379
-
-
Cotzias, G.C.1
Van, W.M.H.2
Schiffer, L.M.3
-
90
-
-
0014673226
-
Modification of Parkinsonism-chronic treatment with L-dopa
-
Cotzias, G.C.; Papavasiliou, P.S.; Gellene, R. Modification of Parkinsonism-chronic treatment with L-dopa. N. Engl. J. Med., 1969, 280, 337-345.
-
(1969)
N. Engl. J. Med.
, vol.280
, pp. 337-345
-
-
Cotzias, G.C.1
Papavasiliou, P.S.2
Gellene, R.3
-
91
-
-
0015151902
-
Treatment of parkinsonism with levodopa Follow-up after 2 years of treatment
-
Lee, J.E.; Sweet, R.D.; McDowell, F.H. Treatment of parkinsonism with levodopa. Follow-up after 2 years of treatment. Ann. Intern. Med., 1971, 75, 703-708.
-
(1971)
Ann. Intern. Med.
, vol.75
, pp. 703-708
-
-
Lee, J.E.1
Sweet, R.D.2
McDowell, F.H.3
-
92
-
-
0014710823
-
Treatment of parkinson's syndrome with ldihydroxyphenylalanine (levodopa)
-
McDowell, F.; Lee, J.E.; Swift, T.; Sweet, R.D.; Ogsbury, J.S.; Kessler, J.T. Treatment of Parkinson's syndrome with Ldihydroxyphenylalanine (levodopa). Ann. Intern. Med., 1970, 72, 29-35.
-
(1970)
Ann. Intern. Med.
, vol.72
, pp. 29-35
-
-
McDowell, F.1
Lee, J.E.2
Swift, T.3
Sweet, R.D.4
Ogsbury, J.S.5
Kessler, J.T.6
-
93
-
-
53149145972
-
The history of dopamine and levodopa in the treatment of Parkinson's disease
-
Fahn, S. The history of dopamine and levodopa in the treatment of Parkinson's disease. Movement Disord., 2008, 23(S3), 497-508.
-
(2008)
Movement Disord.
, vol.23
, Issue.S3
, pp. 497-508
-
-
Fahn, S.1
-
95
-
-
0037176848
-
Levodopa strengths and weaknesses
-
Jankovic, J. Levodopa strengths and weaknesses. Neurology, 2002, 58, 19-32.
-
(2002)
Neurology
, vol.58
, pp. 19-32
-
-
Jankovic, J.1
-
96
-
-
0023404750
-
Clinical pharmacokinetics of antiparkinsonian drugs
-
Cedarbaum, J.M. Clinical pharmacokinetics of antiparkinsonian drugs. Clin. Pharmacokinet., 1987, 13, 141-178.
-
(1987)
Clin. Pharmacokinet.
, vol.13
, pp. 141-178
-
-
Cedarbaum, J.M.1
-
97
-
-
36849055017
-
Monoamine oxidase-b inhibition in the treatment of parkinson's disease
-
Fernandez, H.H.; Chen, J.J. Monoamine oxidase-B inhibition in the treatment of Parkinson's disease. Pharmacotherapy, 2007, 27, 174-185.
-
(2007)
Pharmacotherapy
, vol.27
, pp. 174-185
-
-
Fernandez, H.H.1
Chen, J.J.2
-
98
-
-
9044227267
-
Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease
-
Lees, A.J. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Br. Med. J., 1995, 311, 1602-1607.
-
(1995)
Br. Med. J.
, vol.311
, pp. 1602-1607
-
-
Lees, A.J.1
-
99
-
-
0036231440
-
Impact of sustained deprenyl (selegiline) in levodopatreated parkinson's disease: A randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial
-
Shoulson, I.; Oakes, D.; Fahn, S.; Lang, A.; Langston, J.W.; LeWitt, P.; Olanow, C.W.; Penney, J.B.; Tanner, C.; Kieburtz, K.; Rudolph, A. Impact of sustained deprenyl (selegiline) in levodopatreated Parkinson's disease: A randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Ann. Neurol., 2002, 51, 604-612.
-
(2002)
Ann. Neurol.
, vol.51
, pp. 604-612
-
-
Shoulson, I.1
Oakes, D.2
Fahn, S.3
Lang, A.4
Langston, J.W.5
Lewitt, P.6
Olanow, C.W.7
Penney, J.B.8
Tanner, C.9
Kieburtz, K.10
Rudolph, A.11
-
100
-
-
3242784708
-
Deprenyl in the treatment of symptom fluctuations in advanced parkinson's disease
-
Golbe, L.I.; Lieberman, A.N.; Muenter, M.D.; Ahlskog, J.E.; Gopinathan, G.; Neophytides, A.N.; Foo, S.H.; Duvoisin, R.C. Deprenyl in the treatment of symptom fluctuations in advanced Parkinson's disease. Clin. Neuropharmacol., 1988, 11, 45-55.
-
(1988)
Clin. Neuropharmacol.
, vol.11
, pp. 45-55
-
-
Golbe, L.I.1
Lieberman, A.N.2
Muenter, M.D.3
Ahlskog, J.E.4
Gopinathan, G.5
Neophytides, A.N.6
Foo, S.H.7
Duvoisin, R.C.8
-
101
-
-
15844386001
-
Rasagiline as an adjunct to levodopa in patients with parkinson's disease and motor fluctuations (largo, lasting effect in adjunct therapy with rasagiline given once daily, study): A randomized, double-blind, parallel-group trial
-
Rascol, O.; Brooks, D.J.; Melamed, E.; Oertel, W.; Poewe, W.; Stocchi, F.; Tolosa, E. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomized, double-blind, parallel-group trial. Lancet, 2005, 365, 947-954.
-
(2005)
Lancet
, vol.365
, pp. 947-954
-
-
Rascol, O.1
Brooks, D.J.2
Melamed, E.3
Oertel, W.4
Poewe, W.5
Stocchi, F.6
Tolosa, E.7
-
102
-
-
0041633741
-
Pressor response to intravenous tyramine in healthy subjects after safinamide, a novel neuroprotectant with selective, reversible monoamine oxidase b inhibition
-
Cattaneo, C.; Caccia, C.; Marzo, A.; Maj, R.; Fariello, R.G. Pressor response to intravenous tyramine in healthy subjects after safinamide, a novel neuroprotectant with selective, reversible monoamine oxidase B inhibition. Clin. Neuropharmacol., 2003, 26, 213-217.
-
(2003)
Clin. Neuropharmacol.
, vol.26
, pp. 213-217
-
-
Cattaneo, C.1
Caccia, C.2
Marzo, A.3
Maj, R.4
Fariello, R.G.5
-
103
-
-
33750000049
-
Symptom relief in parkinson disease by safinamide: Biochemical and clinical evidence of efficacy beyond mao-b inhibition
-
Stocchi, F.; Vacca, L.; Grassini, P.; De, P.M.F.; Battaglia, G.; Cattaneo, C.; Fariello, R.G. Symptom relief in Parkinson disease by safinamide: Biochemical and clinical evidence of efficacy beyond MAO-B inhibition. Neurology, 2006, 67, 24-29.
-
(2006)
Neurology
, vol.67
, pp. 24-29
-
-
Stocchi, F.1
Vacca, L.2
Grassini, P.3
De, P.M.F.4
Battaglia, G.5
Cattaneo, C.6
Fariello, R.G.7
-
104
-
-
77955832709
-
Safinamide in the treatment of parkinson's disease
-
Schapira, A.H.V. Safinamide in the treatment of Parkinson's disease. Expert Opin. Pharmacother., 2010, 11, 2261-2268.
-
(2010)
Expert Opin. Pharmacother.
, vol.11
, pp. 2261-2268
-
-
Schapira, A.H.V.1
-
105
-
-
84861760612
-
Role of catechol-O-methyltransferase (COMT)-dependent processes in Parkinson's disease and L-DOPA treatment
-
Espinoza, S.; Manago, F.; Leo, D.; Sotnikova, T.D.; Gainetdinov, R.R. Role of catechol-O-methyltransferase (COMT)-dependent processes in Parkinson's disease and L-DOPA treatment. CNS Neurol. Disord.: Drug Targets, 2012, 11, 251-263.
-
(2012)
CNS Neurol. Disord.: Drug Targets
, vol.11
, pp. 251-263
-
-
Espinoza, S.1
Manago, F.2
Leo, D.3
Sotnikova, T.D.4
Gainetdinov, R.R.5
-
106
-
-
0028137620
-
Effect of entacapone, a peripherally acting catechol-omethyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with parkinson's disease
-
Merello, M.; Lees, A.J.; Webster, R.; Bovingdon, M.; Gordin, A. Effect of entacapone, a peripherally acting catechol-Omethyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson's disease. J. Neurol. Neurosurg. Psychiatry, 1994, 57, 186-189.
-
(1994)
J. Neurol. Neurosurg. Psychiatry
, vol.57
, pp. 186-189
-
-
Merello, M.1
Lees, A.J.2
Webster, R.3
Bovingdon, M.4
Gordin, A.5
-
107
-
-
0031028464
-
Tolcapone improves motor function and reduces levodopa requirement in patients with parkinson's disease experiencing motor fluctuations: A multicenter, double-blind, randomized, placebo-controlled trial
-
Kurth, M.C.; Adler, C.H.; St, H.M.; Singer, C.; Waters, C.; LeWitt, P.; Chernik, D.A.; Dorflinger, E.E.; Yoo, K. Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: A multicenter, double-blind, randomized, placebo-controlled trial. Neurology, 1997, 48, 81-87.
-
(1997)
Neurology
, vol.48
, pp. 81-87
-
-
Kurth, M.C.1
Adler, C.H.2
St, H.M.3
Singer, C.4
Waters, C.5
Lewitt, P.6
Chernik, D.A.7
Dorflinger, E.E.8
Yoo, K.9
-
108
-
-
0028286186
-
Effect of peripheral catechol-o-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients
-
Nutt, J.G.; Woodward, W.R.; Beckner, R.M.; Stone, C.K.; Berggren, K.; Carter, J.H.; Gancher, S.T.; Hammerstad, J.P.; Gordin, A. Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology, 1994, 44, 913-919.
-
(1994)
Neurology
, vol.44
, pp. 913-919
-
-
Nutt, J.G.1
Woodward, W.R.2
Beckner, R.M.3
Stone, C.K.4
Berggren, K.5
Carter, J.H.6
Gancher, S.T.7
Hammerstad, J.P.8
Gordin, A.9
-
109
-
-
33646104205
-
Practice Parameter: Neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review)
-
Suchowersky, O.; Gronseth, G.; Perlmutter, J.; Reich, S.; Zesiewicz, T.; Weiner, W.J. Practice Parameter: Neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review). Neurology, 2006, 66, 976-982.
-
(2006)
Neurology
, vol.66
, pp. 976-982
-
-
Suchowersky, O.1
Gronseth, G.2
Perlmutter, J.3
Reich, S.4
Zesiewicz, T.5
Weiner, W.J.6
-
110
-
-
0034871806
-
Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: Comparison of rasagiline (TVP 1012) with selegiline
-
Kupsch, A.; Sautter, J.; Gotz, M.E.; Breithaupt, W.; Schwarz, J.; Youdim, M.B.H.; Riederer, P.; Gerlach, M.; Oertel, W.H. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline. J. Neural Transm., 2001, 108, 985-1009.
-
(2001)
J. Neural Transm.
, vol.108
, pp. 985-1009
-
-
Kupsch, A.1
Sautter, J.2
Gotz, M.E.3
Breithaupt, W.4
Schwarz, J.5
Youdim, M.B.H.6
Riederer, P.7
Gerlach, M.8
Oertel, W.H.9
-
111
-
-
2342547676
-
Neuroprotective effect of rasagiline in a rodent model of Parkinson's disease
-
Blandini, F.; Armentero, M.T.; Fancellu, R.; Blaugrund, E.; Nappi, G. Neuroprotective effect of rasagiline in a rodent model of Parkinson's disease. Exp. Neurol., 2004, 187, 455-459.
-
(2004)
Exp. Neurol.
, vol.187
, pp. 455-459
-
-
Blandini, F.1
Armentero, M.T.2
Fancellu, R.3
Blaugrund, E.4
Nappi, G.5
-
112
-
-
67649116292
-
New drug delivery strategies for improved parkinson's disease therapy
-
Di, S.A.; Sozio, P.; Iannitelli, A.; Cerasa, L.S. New drug delivery strategies for improved Parkinson's disease therapy. Expert Opin. Drug Del., 2009, 6, 389-404.
-
(2009)
Expert Opin. Drug Del.
, vol.6
, pp. 389-404
-
-
Di, S.A.1
Sozio, P.2
Iannitelli, A.3
Cerasa, L.S.4
-
113
-
-
76149103919
-
Levodopa delivery systems: Advancements in delivery of the gold standard
-
Ngwuluka, N.; Pillay, V.; Du Toit, L.C.; Ndesendo, V.; Choonara, Y.; Modi, G.; Naidoo, D. Levodopa delivery systems: advancements in delivery of the gold standard. Expert Opin. Drug Del., 2010, 7(2), 203-224.
-
(2010)
Expert Opin. Drug Del.
, vol.7
, Issue.2
, pp. 203-224
-
-
Ngwuluka, N.1
Pillay, V.2
Du Toit, L.C.3
Ndesendo, V.4
Choonara, Y.5
Modi, G.6
Naidoo, D.7
-
114
-
-
8044229410
-
Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease: A multicenter 5-year study
-
Block, G.; Liss, C.; Reines, S.; Irr, J.; Nibbelink, D. Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease: a multicenter 5-year study. Eur. Neurol., 1997, 37, 23-27.
-
(1997)
Eur. Neurol.
, vol.37
, pp. 23-27
-
-
Block, G.1
Liss, C.2
Reines, S.3
Irr, J.4
Nibbelink, D.5
-
115
-
-
0141632746
-
Clinical strategies to prevent and delay motor complications
-
Barone, P. Clinical strategies to prevent and delay motor complications. Neurology, 2003, 61, 12-16.
-
(2003)
Neurology
, vol.61
, pp. 12-16
-
-
Barone, P.1
-
116
-
-
12544252127
-
Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease
-
Nyholm, D.; Nilsson, R.A.I.M.; Dizdar, N.; Constantinescu, R.; Holmberg, B.; Jansson, R.; Aquilonius, S.M.; Askmark, H. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology, 2005, 64, 216-223.
-
(2005)
Neurology
, vol.64
, pp. 216-223
-
-
Nyholm, D.1
Nilsson, R.A.I.M.2
Dizdar, N.3
Constantinescu, R.4
Holmberg, B.5
Jansson, R.6
Aquilonius, S.M.7
Askmark, H.8
-
117
-
-
33745386214
-
Long-term 24-hour duodenal infusion of levodopa: Outcome and dose requirements
-
Deleu, D.; Hanssens, Y. Long-term 24-hour duodenal infusion of levodopa: outcome and dose requirements. Neurology, 2006, 66, 1611-1612.
-
(2006)
Neurology
, vol.66
, pp. 1611-1612
-
-
Deleu, D.1
Hanssens, Y.2
-
118
-
-
34648847390
-
Continuous dopaminergic stimulation-from theory to clinical practice
-
Antonini, A. Continuous dopaminergic stimulation-from theory to clinical practice. Parkinsonism Relat. Disord., 2007, 13 24-28.
-
(2007)
Parkinsonism Relat. Disord.
, vol.13
, pp. 24-28
-
-
Antonini, A.1
-
119
-
-
79955622718
-
Priorities in parkinson's disease research
-
Meissner, W.G.; Frasier, M.; Gasser, T.; Goetz, C.G.; Lozano, A.; Piccini, P.; Obeso, J.A.; Rascol, O.; Schapira, A.; Voon, V.; Weiner, D.M.; Tison, F.; Bezard, E. Priorities in Parkinson's disease research. Nat. Rev. Drug Discov., 2011, 10, 377-393.
-
(2011)
Nat. Rev. Drug Discov.
, vol.10
, pp. 377-393
-
-
Meissner, W.G.1
Frasier, M.2
Gasser, T.3
Goetz, C.G.4
Lozano, A.5
Piccini, P.6
Obeso, J.A.7
Rascol, O.8
Schapira, A.9
Voon, V.10
Weiner, D.M.11
Tison, F.12
Bezard, E.13
-
120
-
-
84875271113
-
Extended-release carbidopalevodopa (IPX066) compared with immediate-release carbidopalevodopa in patients with Parkinson's disease and motor fluctuations: A phase 3 randomised, double-blind trial
-
Hauser, R.A.; Hsu, A.; Kell, S.; Espay, A.J.; Sethi, K.; Stacy, M.; Ondo, W.; O'Connell, M.; Gupta, S. Extended-release carbidopalevodopa (IPX066) compared with immediate-release carbidopalevodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial. Lancet Neurol., 2013, 12(4), 346-356.
-
(2013)
Lancet Neurol.
, vol.12
, Issue.4
, pp. 346-356
-
-
Hauser, R.A.1
Hsu, A.2
Kell, S.3
Espay, A.J.4
Sethi, K.5
Stacy, M.6
Ondo, W.7
O'Connell, M.8
Gupta, S.9
-
121
-
-
79960696174
-
A brief history of levodopa
-
Hornykiewicz, O. A brief history of levodopa. J. Neurol., 2010, 257(2), 249-252.
-
(2010)
J. Neurol.
, vol.257
, Issue.2
, pp. 249-252
-
-
Hornykiewicz, O.1
-
122
-
-
65449135642
-
Levodopa: Past, present, and future
-
Hauser, R.A. Levodopa: Past, Present, and Future. Eur. Neurol., 2009, 62, 1-8.
-
(2009)
Eur. Neurol.
, vol.62
, pp. 1-8
-
-
Hauser, R.A.1
-
123
-
-
0014787409
-
Newer medical treatment in parkinsonism
-
Schwarz, G.A.; Fahn, S. Newer medical treatment in parkinsonism. Med. Clin. North Am., 1970, 54, 773-785.
-
(1970)
Med. Clin. North Am.
, vol.54
, pp. 773-785
-
-
Schwarz, G.A.1
Fahn, S.2
-
124
-
-
41749111396
-
Optimizing long-term therapy for parkinson disease: Options for treatment-associated dyskinesia
-
Stacy, M.; Galbreath, A. Optimizing Long-Term Therapy for Parkinson Disease: Options for Treatment-Associated Dyskinesia. Clin. Neuropharmacol., 2008, 31, 120-125.
-
(2008)
Clin. Neuropharmacol.
, vol.31
, pp. 120-125
-
-
Stacy, M.1
Galbreath, A.2
-
125
-
-
38549168908
-
Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa
-
Hauser, R.A.; Rascol, O.; Korczyn, A.D.; Jon, S.A.; Watts, R.L.; Poewe, W.; De, D.P.P.; Lang, A.E. Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. Movement Disord., 2007, 22, 2409-2417.
-
(2007)
Movement Disord.
, vol.22
, pp. 2409-2417
-
-
Hauser, R.A.1
Rascol, O.2
Korczyn, A.D.3
Jon, S.A.4
Watts, R.L.5
Poewe, W.6
De, D.P.P.7
Lang, A.E.8
-
126
-
-
69949085340
-
A reassessment of risks and benefits of dopamine agonists in Parkinson's disease
-
Antonini, A.; Tolosa, E.; Mizuno, Y.; Yamamoto, M.; Poewe, W.H. A reassessment of risks and benefits of dopamine agonists in Parkinson's disease. Lancet Neurol., 2009, 8, 929-937.
-
(2009)
Lancet Neurol.
, vol.8
, pp. 929-937
-
-
Antonini, A.1
Tolosa, E.2
Mizuno, Y.3
Yamamoto, M.4
Poewe, W.H.5
-
127
-
-
0037176885
-
Neuroprotection and dopamine agonists
-
Schapira, A.H.V. Neuroprotection and dopamine agonists. Neurology, 2002, 58, 9-18.
-
(2002)
Neurology
, vol.58
, pp. 9-18
-
-
Schapira, A.H.V.1
-
128
-
-
0036460167
-
Dopamine agonists and neuroprotection in Parkinson's disease
-
Schapira, A.H.V. Dopamine agonists and neuroprotection in Parkinson's disease. Eur. J. Neurol., 2002, 9, 7-14.
-
(2002)
Eur. J. Neurol.
, vol.9
, pp. 7-14
-
-
Schapira, A.H.V.1
-
129
-
-
0033545580
-
Synthesis and dopaminergic properties of benzo-fused analogs of quinpirole and quinelorane
-
Doll, M.K.H.; Nichols, D.E.; Kilts, J.D.; Prioleau, C.; Lawler, C.P.; Lewis, M.M.; Mailman, R.B. Synthesis and Dopaminergic Properties of Benzo-Fused Analogs of Quinpirole and Quinelorane. J. Med. Chem., 1999, 42, 935-940.
-
(1999)
J. Med. Chem.
, vol.42
, pp. 935-940
-
-
Doll, M.K.H.1
Nichols, D.E.2
Kilts, J.D.3
Prioleau, C.4
Lawler, C.P.5
Lewis, M.M.6
Mailman, R.B.7
-
130
-
-
0034632790
-
CoMFA-based prediction of agonist affinities at recombinant wild type versus serine to alanine point mutated D2 dopamine receptors
-
Wilcox, R.E.; Huang, W.-H.; Brusniak, M.-Y.K.; Wilcox, D.M.; Pearlman, R.S.; Teeter, M.M.; DuRand, C.J.; Wiens, B.L.; Neve, K.A. CoMFA-based prediction of agonist affinities at recombinant wild type versus serine to alanine point mutated D2 dopamine receptors. J. Med. Chem., 2000, 43, 3005-3019.
-
(2000)
J. Med. Chem.
, vol.43
, pp. 3005-3019
-
-
Wilcox, R.E.1
Huang, W.-H.2
Brusniak, M.-Y.K.3
Wilcox, D.M.4
Pearlman, R.S.5
Teeter, M.M.6
Durand, C.J.7
Wiens, B.L.8
Neve, K.A.9
-
131
-
-
0025298537
-
Trans-10,11-dihydroxy-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridine: A highly potent selective dopamine D1 full agonist
-
Brewster, W.K.; Nichols, D.E.; Riggs, R.M.; Mottola, D.M.; Lovenberg, T.W.; Lewis, M.H.; Mailman, R.B. Trans-10,11-dihydroxy-5,6,6a,7,8,12b- hexahydrobenzo[a]phenanthridine: a highly potent selective dopamine D1 full agonist. J. Med. Chem., 1990, 33, 1756-1764.
-
(1990)
J. Med. Chem.
, vol.33
, pp. 1756-1764
-
-
Brewster, W.K.1
Nichols, D.E.2
Riggs, R.M.3
Mottola, D.M.4
Lovenberg, T.W.5
Lewis, M.H.6
Mailman, R.B.7
-
132
-
-
0031003929
-
Locomotor inhibition, yawning and vacuous chewing induced by a novel dopamine D2 post-synaptic receptor agonist
-
Smith, H.P.; Nichols, D.E.; Mailman, R.B.; Lawler, C.P. Locomotor inhibition, yawning and vacuous chewing induced by a novel dopamine D2 post-synaptic receptor agonist. Eur. J. Pharmacol., 1997, 323, 27-36.
-
(1997)
Eur. J. Pharmacol.
, vol.323
, pp. 27-36
-
-
Smith, H.P.1
Nichols, D.E.2
Mailman, R.B.3
Lawler, C.P.4
-
133
-
-
84873167479
-
Plausible improvements for selective targeting of dopamine receptors in therapy of Parkinson's disease
-
Luthra, P.M.; Kumar, J.B.S. Plausible improvements for selective targeting of dopamine receptors in therapy of Parkinson's disease. Mini-Rev. Med. Chem., 2012, 12, 1556-1564.
-
(2012)
Mini-Rev. Med. Chem.
, vol.12
, pp. 1556-1564
-
-
Luthra, P.M.1
Kumar, J.B.S.2
-
134
-
-
0027518471
-
Subtypes and localization of dopamine receptors in human brain
-
De, K.J. Subtypes and localization of dopamine receptors in human brain. Neurochem. Int., 1993, 22, 83-93.
-
(1993)
Neurochem. Int.
, vol.22
, pp. 83-93
-
-
De, K.J.1
-
135
-
-
33745052903
-
Pramipexole versus sertraline in the treatment of depression in Parkinson's disease: A national multicenter parallel-group randomized study
-
Barone, P.; Scarzella, L.; Marconi, R.; Antonini, A.; Morgante, L.; Bracco, F.; Zappia, M.; Musch, B. Pramipexole versus sertraline in the treatment of depression in Parkinson's disease: a national multicenter parallel-group randomized study. J. Neurol., 2006, 253, 601-607.
-
(2006)
J. Neurol.
, vol.253
, pp. 601-607
-
-
Barone, P.1
Scarzella, L.2
Marconi, R.3
Antonini, A.4
Morgante, L.5
Bracco, F.6
Zappia, M.7
Musch, B.8
-
136
-
-
0030828275
-
Antidepressant effects of pramipexole, a novel dopamine receptor agonist
-
Maj, J.; Rogoz, Z.; Skuza, G.; Kolodziejczyk, K. Antidepressant effects of pramipexole, a novel dopamine receptor agonist. J. Neural Transm., 1997, 104, 525-533.
-
(1997)
J. Neural Transm.
, vol.104
, pp. 525-533
-
-
Maj, J.1
Rogoz, Z.2
Skuza, G.3
Kolodziejczyk, K.4
-
137
-
-
33745098959
-
D1 and functionally selective dopamine agonists as neuroprotective agents in Parkinson's disease
-
Lewis, M.M.; Huang, X.; Nichols, D.E.; Mailman, R.B. D1 and functionally selective dopamine agonists as neuroprotective agents in Parkinson's disease. CNS Neurol. Disord.: Drug Targets, 2006, 5, 345-353.
-
(2006)
CNS Neurol. Disord.: Drug Targets
, vol.5
, pp. 345-353
-
-
Lewis, M.M.1
Huang, X.2
Nichols, D.E.3
Mailman, R.B.4
-
138
-
-
0034801739
-
Choosing dopamine agonists in Parkinson's disease
-
Tan, E.-K.; Jankovic, J. Choosing dopamine agonists in Parkinson's disease. Clin. Neuropharmacol., 2001, 24, 247-253.
-
(2001)
Clin. Neuropharmacol.
, vol.24
, pp. 247-253
-
-
Tan, E.-K.1
Jankovic, J.2
-
139
-
-
0141649537
-
Cabergoline, pramipexole and ropinirole used as monotherapy in early Parkinson's disease: An evidence-based comparison
-
Inzelberg, R.; Schechtman, E.; Nisipeanu, P. Cabergoline, pramipexole and ropinirole used as monotherapy in early Parkinson's disease: an evidence-based comparison. Drugs Aging, 2003, 20, 847-855.
-
(2003)
Drugs Aging
, vol.20
, pp. 847-855
-
-
Inzelberg, R.1
Schechtman, E.2
Nisipeanu, P.3
-
140
-
-
11144354035
-
Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease
-
Van, C.G.; Flamez, A.; Cosyns, B.; Weytjens, C.; Muyldermans, L.; Van, Z.M.; De, S.J.; Santens, P.; Decoodt, P.; Moerman, C.; Schoors, D. Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease. Lancet, 2004, 363, 1179-1183.
-
(2004)
Lancet
, vol.363
, pp. 1179-1183
-
-
Van, C.G.1
Flamez, A.2
Cosyns, B.3
Weytjens, C.4
Muyldermans, L.5
Van, Z.M.6
De, S.J.7
Santens, P.8
Decoodt, P.9
Moerman, C.10
Schoors, D.11
-
141
-
-
3242763710
-
Jr., Pergolide use in Parkinson disease is associated with cardiac valve regurgitation
-
Baseman, D.G.; O'Suilleabhain, P.E.; Reimold, S.C.; Laskar, S.R.; Baseman, J.G.; Dewey, R.B. Jr., Pergolide use in Parkinson disease is associated with cardiac valve regurgitation. Neurology, 2004, 63, 301-304.
-
(2004)
Neurology
, vol.63
, pp. 301-304
-
-
Baseman, D.G.1
O'Suilleabhain, P.E.2
Reimold, S.C.3
Laskar, S.R.4
Baseman, J.G.5
Dewey, R.B.6
-
142
-
-
4444351812
-
Severe multivalvular heart disease: A new complication of the ergot derivative dopamine agonists
-
Horvath, J.; Fross, R.D.; Kleiner-Fisman, G.; Lerch, R.; Stalder, H.; Liaudat, S.; Raskoff, W.J.; Flachsbart, K.D.; Rakowski, H.; Pache, J.-C.; Burkhard, P.R.; Lang, A.E. Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists. Movement Disord., 2004, 19, 656-662.
-
(2004)
Movement Disord.
, vol.19
, pp. 656-662
-
-
Horvath, J.1
Fross, R.D.2
Kleiner-Fisman, G.3
Lerch, R.4
Stalder, H.5
Liaudat, S.6
Raskoff, W.J.7
Flachsbart, K.D.8
Rakowski, H.9
Pache, J.-C.10
Burkhard, P.R.11
Lang, A.E.12
-
143
-
-
0038390136
-
Fibrosis associated with dopamine agonist therapy in Parkinson's disease
-
Müller, T.; Fritze, J. Fibrosis associated with dopamine agonist therapy in Parkinson's disease. Clin. Neuropharmacol., 2003, 26, 109-111.
-
(2003)
Clin. Neuropharmacol.
, vol.26
, pp. 109-111
-
-
Müller, T.1
Fritze, J.2
-
144
-
-
33748522433
-
A review of the receptorbinding and pharmacokinetic properties of dopamine agonists
-
Kvernmo, T.; Hartter, S.; Burger, E. A review of the receptorbinding and pharmacokinetic properties of dopamine agonists. Clin. Ther., 2006, 28, 1065-1078.
-
(2006)
Clin. Ther.
, vol.28
, pp. 1065-1078
-
-
Kvernmo, T.1
Hartter, S.2
Burger, E.3
-
145
-
-
33845974147
-
Valvular heart disease and the use of dopamine agonists for Parkinson's disease
-
Zanettini, R.; Antonini, A.; Gatto, G.; Gentile, R.; Tesei, S.; Pezzoli, G. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N. Engl. J. Med., 2007, 356, 39-46.
-
(2007)
N. Engl. J. Med.
, vol.356
, pp. 39-46
-
-
Zanettini, R.1
Antonini, A.2
Gatto, G.3
Gentile, R.4
Tesei, S.5
Pezzoli, G.6
-
146
-
-
63149158721
-
Severe mitral valve regurgitation with fatal cardiogenic shock in a patient on long-term cabergoline treatment
-
Luedde, M.; Helmke, B.; Katus, H.A.; Frey, N. Severe mitral valve regurgitation with fatal cardiogenic shock in a patient on long-term cabergoline treatment. Int. J. Cardiol., 2009, 133, e97-98.
-
(2009)
Int. J. Cardiol.
, vol.133
-
-
Luedde, M.1
Helmke, B.2
Katus, H.A.3
Frey, N.4
-
147
-
-
33750079581
-
Rotigotine for the treatment of parkinson's disease
-
Morgan, J.C.; Sethi, K.D. Rotigotine for the treatment of Parkinson's disease. Expert Rev. Neurother., 2006, 6, 1275-1282.
-
(2006)
Expert Rev. Neurother.
, vol.6
, pp. 1275-1282
-
-
Morgan, J.C.1
Sethi, K.D.2
-
148
-
-
0036490942
-
Allosteric binding sites on cell-surface receptors: Novel targets for drug discovery
-
Christopoulos, A. Allosteric binding sites on cell-surface receptors: novel targets for drug discovery. Nat. Rev. Drug Discov., 2002, 1, 198-210.
-
(2002)
Nat. Rev. Drug Discov.
, vol.1
, pp. 198-210
-
-
Christopoulos, A.1
-
149
-
-
70350464948
-
Allosteric modulators of G protein-coupled receptors: Future therapeutics for complex physiological disorders
-
Wang, L.; Martin, B.; Brenneman, R.; Luttrell, L.M.; Maudsley, S. Allosteric modulators of G protein-coupled receptors: future therapeutics for complex physiological disorders. J. Pharmacol. Exp. Ther., 2009, 331, 340-348.
-
(2009)
J. Pharmacol. Exp. Ther.
, vol.331
, pp. 340-348
-
-
Wang, L.1
Martin, B.2
Brenneman, R.3
Luttrell, L.M.4
Maudsley, S.5
-
150
-
-
67650489125
-
Orthosteric/allosteric bitopic ligands: Going hybrid at GPCRs
-
Valant, C.; Sexton, P.M.; Christopoulos, A. Orthosteric/allosteric bitopic ligands: going hybrid at GPCRs. Mol. Interv., 2009, 9(3), 125-135.
-
(2009)
Mol. Interv.
, vol.9
, Issue.3
, pp. 125-135
-
-
Valant, C.1
Sexton, P.M.2
Christopoulos, A.3
-
151
-
-
84855879360
-
The best of both worlds? Bitopic orthosteric/allosteric ligands of G proteincoupled receptors
-
Valant, C.; Lane, J.R.; Sexton, P.M.; Christopoulos, A. The best of both worlds? Bitopic orthosteric/allosteric ligands of G proteincoupled receptors. Annu. Rev. Pharmacol. Toxicol., 2012, 52, 153-178.
-
(2012)
Annu. Rev. Pharmacol. Toxicol.
, vol.52
, pp. 153-178
-
-
Valant, C.1
Lane, J.R.2
Sexton, P.M.3
Christopoulos, A.4
-
152
-
-
79957596498
-
Design strategies for bivalent ligands targeting GPCRs
-
Shonberg, J.; Scammells, P.J.; Capuano, B. Design Strategies for Bivalent Ligands Targeting GPCRs. ChemMedChem, 2011, 6(6), 963-974.
-
(2011)
ChemMedChem
, vol.6
, Issue.6
, pp. 963-974
-
-
Shonberg, J.1
Scammells, P.J.2
Capuano, B.3
-
153
-
-
57349190625
-
Bivalent ligands as specific pharmacological tools for g-protein-coupled receptor dimers
-
Berque-Bestel, I.; Lezoulac'h, F.; Jockers, R. Bivalent Ligands as Specific Pharmacological Tools for G-Protein-Coupled Receptor Dimers. Curr. Drug Discovery Technol., 2008, 5(312-318), 312.
-
(2008)
Curr. Drug Discovery Technol.
, vol.5
, Issue.312-318
, pp. 312
-
-
Berque-Bestel, I.1
Lezoulac'H, F.2
Jockers, R.3
-
154
-
-
84872048999
-
The potential for selective pharmacological therapies through biased receptor signaling
-
Kenakin, T. The potential for selective pharmacological therapies through biased receptor signaling. BMC Pharmacol. Toxicol., 2012, 13, 3.
-
(2012)
BMC Pharmacol. Toxicol.
, vol.13
, pp. 3
-
-
Kenakin, T.1
-
155
-
-
84875227396
-
Signalling bias in new drug discovery: Detection, quantification and therapeutic impact
-
Kenakin, T.; Christopoulos, A. Signalling bias in new drug discovery: detection, quantification and therapeutic impact. Nat. Rev. Drug Discov., 2013, 12, 205-216.
-
(2013)
Nat. Rev. Drug Discov.
, vol.12
, pp. 205-216
-
-
Kenakin, T.1
Christopoulos, A.2
-
156
-
-
58149193205
-
Allosteric modulators of GPCRs: A novel approach for the treatment of CNS disorders
-
Conn, P.J.; Christopoulos, A.; Lindsley, C.W. Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nat. Rev. Drug Discov., 2009, 8, 41-54.
-
(2009)
Nat. Rev. Drug Discov.
, vol.8
, pp. 41-54
-
-
Conn, P.J.1
Christopoulos, A.2
Lindsley, C.W.3
-
157
-
-
84857759143
-
The different ways through which specificity works in orthosteric and allosteric drugs
-
Nussinov, R.; Tsai, C.-J. The different ways through which specificity works in orthosteric and allosteric drugs. Curr. Pharm. Des., 2012, 18, 1311-1316.
-
(2012)
Curr. Pharm. Des.
, vol.18
, pp. 1311-1316
-
-
Nussinov, R.1
Tsai, C.-J.2
-
158
-
-
0036208986
-
The Calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism
-
Goodman, W.G.; Hladik, G.A.; Turner, S.A.; Blaisdell, P.W.; Goodkin, D.A.; Liu, W.; Barri, Y.M.; Cohen, R.M.; Coburn, J.W. The Calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J. Am. Soc. Nephrol., 2002, 13, 1017-1024.
-
(2002)
J. Am. Soc. Nephrol.
, vol.13
, pp. 1017-1024
-
-
Goodman, W.G.1
Hladik, G.A.2
Turner, S.A.3
Blaisdell, P.W.4
Goodkin, D.A.5
Liu, W.6
Barri, Y.M.7
Cohen, R.M.8
Coburn, J.W.9
-
159
-
-
27744548649
-
The discovery of the CCR5 receptor antagonist, UK-427,857, a new agent for the treatment of HIV infection and AIDS
-
Wood, A.; Armour, D. The discovery of the CCR5 receptor antagonist, UK-427,857, a new agent for the treatment of HIV infection and AIDS. Prog. Med. Chem., 2005, 43, 239-271.
-
(2005)
Prog. Med. Chem.
, vol.43
, pp. 239-271
-
-
Wood, A.1
Armour, D.2
-
160
-
-
0344875553
-
Adenosine a2adopamine d2 recetor-receptor heteromerization-qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer
-
Canals, M.; Marcellino, D.; Fanelli, F.; Ciruela, F.; de Benedetti, P.; Goldberg, S.R.; Neve, K.; Fuxe, K.; Agnati, L.; Woods, A.S.; Ferre, S.; Lluís, C.; Bouvier, M.; Franco, R. Adenosine A2ADopamine D2 Recetor-Receptor Heteromerization-Qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer. J. Biol. Chem., 2003, 278, 46741-46749.
-
(2003)
J. Biol. Chem.
, vol.278
, pp. 46741-46749
-
-
Canals, M.1
Marcellino, D.2
Fanelli, F.3
Ciruela, F.4
De Benedetti, P.5
Goldberg, S.R.6
Neve, K.7
Fuxe, K.8
Agnati, L.9
Woods, A.S.10
Ferre, S.11
Lluís, C.12
Bouvier, M.13
Franco, R.14
-
161
-
-
84861553696
-
Pathophysiology of GPCR homo-and hetero-dimerization: Special emphasis on somatostatin receptors
-
Somvanshi, R.K.; Kumar, U. Pathophysiology of GPCR homo-and hetero-dimerization: special emphasis on somatostatin receptors. Pharmaceuticals, 2012, 5, 417-446.
-
(2012)
Pharmaceuticals
, vol.5
, pp. 417-446
-
-
Somvanshi, R.K.1
Kumar, U.2
-
162
-
-
0034682445
-
Dopamine D1 and adenosine A1 receptors form functionally interacting heteromeric complexes
-
Gines, S.; Hillion, J.; Torvinen, M.; Le, C.S.; Casado, V.; Canela, E.I.; Rondin, S.; Lew, J.Y.; Watson, S.; Zoli, M.; Agnati, L.F.; Vernier, P.; Lluis, C.; Ferre, S.; Fuxe, K.; Franco, R. Dopamine D1 and adenosine A1 receptors form functionally interacting heteromeric complexes. Proc. Natl. Acad. Sci. U. S. A., 2000, 97, 8606-8611.
-
(2000)
Proc. Natl. Acad. Sci. U. S. A.
, vol.97
, pp. 8606-8611
-
-
Gines, S.1
Hillion, J.2
Torvinen, M.3
Le, C.S.4
Casado, V.5
Canela, E.I.6
Rondin, S.7
Lew, J.Y.8
Watson, S.9
Zoli, M.10
Agnati, L.F.11
Vernier, P.12
Lluis, C.13
Ferre, S.14
Fuxe, K.15
Franco, R.16
-
163
-
-
0034616021
-
Receptors for dopamine and somatostatin: Formation of hetero-oligomers with enhanced functional activity
-
Rocheville, M.; Lange, D.C.; Kumar, U.; Patel, S.C.; Patel, R.C.; Patel, Y.C. Receptors for dopamine and somatostatin: Formation of hetero-oligomers with enhanced functional activity. Science, 2000, 288, 154-157.
-
(2000)
Science
, vol.288
, pp. 154-157
-
-
Rocheville, M.1
Lange, D.C.2
Kumar, U.3
Patel, S.C.4
Patel, R.C.5
Patel, Y.C.6
-
164
-
-
79955878044
-
From models to molecules: Opioid receptor dimers, bivalent ligands, and selective opioid receptor probes [erratum to document cited in ca135:116529]
-
Portoghese, P.S. From Models to Molecules: opioid receptor dimers, bivalent ligands, and selective opioid receptor probes. [Erratum to document cited in CA135:116529]. J. Med. Chem., 2001, 44, 3758.
-
(2001)
J. Med. Chem.
, vol.44
, pp. 3758
-
-
Portoghese, P.S.1
-
165
-
-
84857430512
-
Homobivalent ligands of the atypical antipsychotic clozapine: Design, synthesis, and pharmacological evaluation
-
McRobb, F.M.; Crosby, I.T.; Yuriev, E.; Lane, J.R.; Capuano, B. Homobivalent ligands of the atypical antipsychotic clozapine: design, synthesis, and pharmacological evaluation. J. Med. Chem., 2012, 55, 1622-1634.
-
(2012)
J. Med. Chem.
, vol.55
, pp. 1622-1634
-
-
McRobb, F.M.1
Crosby, I.T.2
Yuriev, E.3
Lane, J.R.4
Capuano, B.5
-
166
-
-
79960172993
-
Bivalent dopamine D2 receptor ligands: Synthesis and binding properties
-
Kü hhorn, J.; Hü bner, H.; Gmeiner, P. Bivalent Dopamine D2 Receptor Ligands: Synthesis and Binding Properties. J. Med. Chem., 2011, 54, 4896-4903.
-
(2011)
J. Med. Chem.
, vol.54
, pp. 4896-4903
-
-
Kü Hhorn, J.1
Hü Bner, H.2
Gmeiner, P.3
-
167
-
-
34447626644
-
GPCR functional selectivity has therapeutic impact
-
Mailman, R.B. GPCR functional selectivity has therapeutic impact. Trends Pharmacol. Sci., 2007, 28, 390-396.
-
(2007)
Trends Pharmacol. Sci.
, vol.28
, pp. 390-396
-
-
Mailman, R.B.1
-
168
-
-
33751162165
-
Distinct signaling profiles of -1 and -2 adrenergic receptor ligands toward adenylyl cyclase and mitogenactivated protein kinase reveals the multidimensionality of efficacy
-
Galandrin, S.; Bouvier, M. Distinct signaling profiles of -1 and -2 adrenergic receptor ligands toward adenylyl cyclase and mitogenactivated protein kinase reveals the multidimensionality of efficacy. Mol. Pharmacol., 2006, 70, 1575-1584.
-
(2006)
Mol. Pharmacol.
, vol.70
, pp. 1575-1584
-
-
Galandrin, S.1
Bouvier, M.2
-
169
-
-
77952354490
-
Seven transmembrane receptors as shapeshifting proteins: The impact of allosteric modulation and functional selectivity on new drug discovery
-
Kenakin, T.; Miller, L.J. Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery. Pharmacol. Rev., 2010, 62, 265-304.
-
(2010)
Pharmacol. Rev.
, vol.62
, pp. 265-304
-
-
Kenakin, T.1
Miller, L.J.2
-
170
-
-
30444456827
-
Design and synthesis of photoaffinity-labeling ligands of the l-prolyl-l-leucylglycinamide binding site involved in the allosteric modulation of the dopamine receptor
-
Fisher, A.; Mann, A.; Verma, V.; Thomas, N.; Mishra, R.K.; Johnson, R.L. Design and Synthesis of Photoaffinity-Labeling Ligands of the L-Prolyl-L-leucylglycinamide Binding Site Involved in the Allosteric Modulation of the Dopamine Receptor. J. Med. Chem., 2006, 49, 307-317.
-
(2006)
J. Med. Chem.
, vol.49
, pp. 307-317
-
-
Fisher, A.1
Mann, A.2
Verma, V.3
Thomas, N.4
Mishra, R.K.5
Johnson, R.L.6
-
171
-
-
0023870799
-
Interaction of L-prolyl-L-leucyl glycinamide with dopamine D2 receptor: Evidence for modulation of agonist affinity states in bovine striatal membranes
-
Srivastava, L.K.; Bajwa, S.B.; Johnson, R.L.; Mishra, R.K. Interaction of L-prolyl-L-leucyl glycinamide with dopamine D2 receptor: evidence for modulation of agonist affinity states in bovine striatal membranes. J. Neurochem., 1988, 50, 960-968.
-
(1988)
J. Neurochem.
, vol.50
, pp. 960-968
-
-
Srivastava, L.K.1
Bajwa, S.B.2
Johnson, R.L.3
Mishra, R.K.4
-
172
-
-
27744575172
-
Modulation of agonist binding to human dopamine receptor subtypes by l-prolyl-lleucyl-glycinamide and a peptidomimetic analog
-
Verma, V.; Mann, A.; Costain, W.; Pontoriero, G.; Castellano, J.M.; Skoblenick, K.; Gupta, S.K.; Pristupa, Z.; Niznik, H.B.; Johnson, R.L.; Nair, V.D.; Mishra, R.K. Modulation of agonist binding to human dopamine receptor subtypes by L-prolyl-Lleucyl-glycinamide and a peptidomimetic analog. J. Pharmacol. Exp. Ther., 2005, 315, 1228-1236.
-
(2005)
J. Pharmacol. Exp. Ther.
, vol.315
, pp. 1228-1236
-
-
Verma, V.1
Mann, A.2
Costain, W.3
Pontoriero, G.4
Castellano, J.M.5
Skoblenick, K.6
Gupta, S.K.7
Pristupa, Z.8
Niznik, H.B.9
Johnson, R.L.10
Nair, V.D.11
Mishra, R.K.12
-
173
-
-
84873480917
-
Development of peptidomimetic ligands of Pro-Leu-Gly-NH2 as allosteric modulators of the dopamine D2 receptor
-
Bhagwanth, S.; Mishra, R.K.; Johnson, R.L. Development of peptidomimetic ligands of Pro-Leu-Gly-NH2 as allosteric modulators of the dopamine D2 receptor. Beilstein J. Org. Chem., 2013, 9, 204-214.
-
(2013)
Beilstein J. Org. Chem.
, vol.9
, pp. 204-214
-
-
Bhagwanth, S.1
Mishra, R.K.2
Johnson, R.L.3
-
174
-
-
84859885147
-
Transformation of Pro-Leu-Gly-NH2 peptidomimetic positive allosteric modulators of the dopamine D2 receptor into negative modulators
-
Bhagwanth, S.; Mishra, S.; Daya, R.; Mah, J.; Mishra, R.K.; Johnson, R.L. Transformation of Pro-Leu-Gly-NH2 Peptidomimetic Positive Allosteric Modulators of the Dopamine D2 Receptor into Negative Modulators. ACS Chem. Neurosci., 2012, 3, 274-284.
-
(2012)
ACS Chem. Neurosci.
, vol.3
, pp. 274-284
-
-
Bhagwanth, S.1
Mishra, S.2
Daya, R.3
Mah, J.4
Mishra, R.K.5
Johnson, R.L.6
-
175
-
-
71049142202
-
1,1'-disubstituted ferrocenes as molecular hinges in mono-and bivalent dopamine receptor ligands
-
Huber, D.; Hubner, H.; Gmeiner, P. 1,1'-Disubstituted Ferrocenes as Molecular Hinges in Mono-and Bivalent Dopamine Receptor Ligands. J. Med. Chem., 2009, 52, 6860-6870.
-
(2009)
J. Med. Chem.
, vol.52
, pp. 6860-6870
-
-
Huber, D.1
Hubner, H.2
Gmeiner, P.3
-
176
-
-
84855186679
-
Bivalent molecular probes for dopamine D2-like receptors
-
Huber, D.; Loeber, S.; Huebner, H.; Gmeiner, P. Bivalent molecular probes for dopamine D2-like receptors. Bioorg. Med. Chem., 2012, 20, 455-466.
-
(2012)
Bioorg. Med. Chem.
, vol.20
, pp. 455-466
-
-
Huber, D.1
Loeber, S.2
Huebner, H.3
Gmeiner, P.4
-
177
-
-
81555228201
-
Development of a bivalent dopamine D2 receptor agonist
-
Kuehhorn, J.; Goetz, A.; Huebner, H.; Thompson, D.; Whistler, J.; Gmeiner, P. Development of a Bivalent Dopamine D2 Receptor Agonist. J. Med. Chem., 2011, 54, 7911-7919.
-
(2011)
J. Med. Chem.
, vol.54
, pp. 7911-7919
-
-
Kuehhorn, J.1
Goetz, A.2
Huebner, H.3
Thompson, D.4
Whistler, J.5
Gmeiner, P.6
-
178
-
-
84871255186
-
Novel bivalent ligands for D2/D3 dopamine receptors: Significant cooperative gain in d2 affinity and potency
-
Gogoi, S.; Biswas, S.; Modi, G.; Antonio, T.; Reith, M.E.A.; Dutta, A.K. Novel Bivalent Ligands for D2/D3 Dopamine Receptors: Significant Cooperative Gain in D2 Affinity and Potency. ACS Med. Chem. Lett., 2012, 3(12), 991-996.
-
(2012)
ACS Med. Chem. Lett.
, vol.3
, Issue.12
, pp. 991-996
-
-
Gogoi, S.1
Biswas, S.2
Modi, G.3
Antonio, T.4
Reith, M.E.A.5
Dutta, A.K.6
-
179
-
-
33845903110
-
Functional selectivity and classical concepts of quantitative pharmacology
-
Urban, J.D.; Clarke, W.P.; von, Z.M.; Nichols, D.E.; Kobilka, B.; Weinstein, H.; Javitch, J.A.; Roth, B.L.; Christopoulos, A.; Sexton, P.M.; Miller, K.J.; Spedding, M.; Mailman, R.B. Functional selectivity and classical concepts of quantitative pharmacology. J. Pharmacol. Exp. Ther., 2007, 320, 1-13.
-
(2007)
J. Pharmacol. Exp. Ther.
, vol.320
, pp. 1-13
-
-
Urban, J.D.1
Clarke, W.P.2
Von, Z.M.3
Nichols, D.E.4
Kobilka, B.5
Weinstein, H.6
Javitch, J.A.7
Roth, B.L.8
Christopoulos, A.9
Sexton, P.M.10
Miller, K.J.11
Spedding, M.12
Mailman, R.B.13
-
180
-
-
0026643520
-
Dihydrexidine, a novel full efficacy D1 dopamine receptor agonist
-
Mottola, D.M.; Brewster, W.K.; Cook, L.L.; Nichols, D.E.; Mailman, R.B. Dihydrexidine, a novel full efficacy D1 dopamine receptor agonist. J. Pharmacol. Exp. Ther., 1992, 262, 383-393.
-
(1992)
J. Pharmacol. Exp. Ther.
, vol.262
, pp. 383-393
-
-
Mottola, D.M.1
Brewster, W.K.2
Cook, L.L.3
Nichols, D.E.4
Mailman, R.B.5
-
181
-
-
0036088704
-
Functional selectivity of dopamine receptor agonists I. Selective activation of postsynaptic dopamine D2 receptors linked to adenylate cyclase. [Erratum to document cited in CA137:362973]
-
Mottola, D.M.; Kilts, J.D.; Lewis, M.M.; Connery, H.S.; Walker, Q.D.; Jones, S.R.; Booth, R.G.; Hyslop, D.K.; Piercey, M.; Wightman, R.M.; Lawler, C.P.; Nichols, D.E.; Mailman, R.B. Functional selectivity of dopamine receptor agonists. I. Selective activation of postsynaptic dopamine D2 receptors linked to adenylate cyclase. [Erratum to document cited in CA137:362973]. J. Pharmacol. Exp. Ther., 2002, 302, 406.
-
(2002)
J. Pharmacol. Exp. Ther.
, vol.302
, pp. 406
-
-
Mottola, D.M.1
Kilts, J.D.2
Lewis, M.M.3
Connery, H.S.4
Walker, Q.D.5
Jones, S.R.6
Booth, R.G.7
Hyslop, D.K.8
Piercey, M.9
Wightman, R.M.10
Lawler, C.P.11
Nichols, D.E.12
Mailman, R.B.13
-
182
-
-
0036267278
-
Functional selectivity of dopamine receptor agonists II. Actions of dihydrexidine in D2L receptortransfected MN9D cells and pituitary lactotrophs
-
Kilts, J.D.; Connery, H.S.; Arrington, E.G.; Lewis, M.M.; Lawler, C.P.; Oxford, G.S.; O'Malley, K.L.; Todd, R.D.; Blake, B.L.; Nichols, D.E.; Mailman, R.B. Functional selectivity of dopamine receptor agonists. II. Actions of dihydrexidine in D2L receptortransfected MN9D cells and pituitary lactotrophs. J. Pharmacol. Exp. Ther., 2002, 301, 1179-1189.
-
(2002)
J. Pharmacol. Exp. Ther.
, vol.301
, pp. 1179-1189
-
-
Kilts, J.D.1
Connery, H.S.2
Arrington, E.G.3
Lewis, M.M.4
Lawler, C.P.5
Oxford, G.S.6
O'Malley, K.L.7
Todd, R.D.8
Blake, B.L.9
Nichols, D.E.10
Mailman, R.B.11
-
183
-
-
3042630989
-
Functional selectivity of D2 receptor ligands in a Chinese hamster ovary hD2L cell line: Evidence for induction of ligandspecific receptor states
-
Gay, E.A.; Urban, J.D.; Nichols, D.E.; Oxford, G.S.; Mailman, R.B. Functional selectivity of D2 receptor ligands in a Chinese hamster ovary hD2L cell line: Evidence for induction of ligandspecific receptor states. Mol. Pharmacol., 2004, 66, 97-105.
-
(2004)
Mol. Pharmacol.
, vol.66
, pp. 97-105
-
-
Gay, E.A.1
Urban, J.D.2
Nichols, D.E.3
Oxford, G.S.4
Mailman, R.B.5
-
184
-
-
78449305788
-
Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist
-
Chien, E.Y.T.; Liu, W.; Zhao, Q.; Katritch, V.; Won, H.G.; Hanson, M.A.; Shi, L.; Newman, A.H.; Javitch, J.A.; Cherezov, V.; Stevens, R.C. Structure of the Human Dopamine D3 Receptor in Complex with a D2/D3 Selective Antagonist. Science, 2010, 330, 1091-1095.
-
(2010)
Science
, vol.330
, pp. 1091-1095
-
-
Chien, E.Y.T.1
Liu, W.2
Zhao, Q.3
Katritch, V.4
Won, H.G.5
Hanson, M.A.6
Shi, L.7
Newman, A.H.8
Javitch, J.A.9
Cherezov, V.10
Stevens, R.C.11
-
185
-
-
0042474326
-
Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTPlesioned primate model of Parkinson's disease
-
Savola, J.-M.; Hill, M.; Engstrom, M.; Merivuori, H.; Wurster, S.; McGuire, S.G.; Fox, S.H.; Crossman, A.R.; Brotchie, J.M. Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTPlesioned primate model of Parkinson's disease. Movement Disord., 2003, 18, 872-883.
-
(2003)
Movement Disord.
, vol.18
, pp. 872-883
-
-
Savola, J.-M.1
Hill, M.2
Engstrom, M.3
Merivuori, H.4
Wurster, S.5
McGuire, S.G.6
Fox, S.H.7
Crossman, A.R.8
Brotchie, J.M.9
-
186
-
-
84866249555
-
Randomized clinical trial of fipamezole for dyskinesia in Parkinson disease (FJORD study)
-
LeWitt, P.A.; Hauser, R.A.; Lu, M.; Nicholas, A.P.; Weiner, W.; Coppard, N.; Leinonen, M.; Savola, J.-M. Randomized clinical trial of fipamezole for dyskinesia in Parkinson disease (FJORD study). Neurology, 2012, 79, 163-169.
-
(2012)
Neurology
, vol.79
, pp. 163-169
-
-
Lewitt, P.A.1
Hauser, R.A.2
Lu, M.3
Nicholas, A.P.4
Weiner, W.5
Coppard, N.6
Leinonen, M.7
Savola, J.-M.8
-
187
-
-
77955380256
-
Maladaptive striatal plasticity in LDOPA-induced dyskinesia
-
Cenci, M.A.; Konradi, C. Maladaptive striatal plasticity in LDOPA-induced dyskinesia. Prog. Brain Res., 2010, 183, 209-233.
-
(2010)
Prog. Brain Res.
, vol.183
, pp. 209-233
-
-
Cenci, M.A.1
Konradi, C.2
-
188
-
-
67649847847
-
Pharmacological modulation of glutamate transmission in a rat model of L-DOPA-induced dyskinesia: Effects on motor behavior and striatal nuclear signaling
-
Rylander, D.; Recchia, A.; Mela, F.; Dekundy, A.; Danysz, W.; Cenci, M.A. Pharmacological modulation of glutamate transmission in a rat model of L-DOPA-induced dyskinesia: effects on motor behavior and striatal nuclear signaling. J. Pharmacol. Exp. Ther., 2009, 330, 227-235.
-
(2009)
J. Pharmacol. Exp. Ther.
, vol.330
, pp. 227-235
-
-
Rylander, D.1
Recchia, A.2
Mela, F.3
Dekundy, A.4
Danysz, W.5
Cenci, M.A.6
-
189
-
-
82955189290
-
Glutamatergic mechanisms in the dyskinesias induced by pharmacological dopamine replacement and deep brain stimulation for the treatment of Parkinson's disease
-
Sgambato-Faure, V.; Cenci, M.A. Glutamatergic mechanisms in the dyskinesias induced by pharmacological dopamine replacement and deep brain stimulation for the treatment of Parkinson's disease. Prog. Neurobiol. (Oxford, U. K.), 2012, 96, 69-86.
-
(2012)
Prog. Neurobiol. (Oxford, U. K.)
, vol.96
, pp. 69-86
-
-
Sgambato-Faure, V.1
Cenci, M.A.2
-
190
-
-
77951958360
-
Safety and efficacy of perampanel in advanced Parkinson's disease: A randomized, placebo-controlled study
-
Eggert, K.; Squillacote, D.; Barone, P.; Dodel, R.; Katzenschlager, R.; Emre, M.; Lees, A.J.; Rascol, O.; Poewe, W.; Tolosa, E.; Trenkwalder, C.; Onofrj, M.; Stocchi, F.; Nappi, G.; Kostic, V.; Potic, J.; Ruzicka, E.; Oertel, W. Safety and efficacy of perampanel in advanced Parkinson's disease: a randomized, placebo-controlled study. Movement Disord., 2010, 25, 896-905.
-
(2010)
Movement Disord.
, vol.25
, pp. 896-905
-
-
Eggert, K.1
Squillacote, D.2
Barone, P.3
Dodel, R.4
Katzenschlager, R.5
Emre, M.6
Lees, A.J.7
Rascol, O.8
Poewe, W.9
Tolosa, E.10
Trenkwalder, C.11
Onofrj, M.12
Stocchi, F.13
Nappi, G.14
Kostic, V.15
Potic, J.16
Ruzicka, E.17
Oertel, W.18
-
191
-
-
84856952320
-
Perampanel, an AMPA antagonist, found to have no benefit in reducing "off" time in Parkinson's disease
-
Lees, A.; Fahn, S.; Eggert, K.M.; Jankovic, J.; Lang, A.; Micheli, F.; Mouradian, M.M.; Oertel, W.H.; Olanow, C.W.; Poewe, W.; Rascol, O.; Tolosa, E.; Squillacote, D.; Kumar, D. Perampanel, an AMPA antagonist, found to have no benefit in reducing "off" time in Parkinson's disease. Movement Disord., 2012, 27, 284-288.
-
(2012)
Movement Disord.
, vol.27
, pp. 284-288
-
-
Lees, A.1
Fahn, S.2
Eggert, K.M.3
Jankovic, J.4
Lang, A.5
Micheli, F.6
Mouradian, M.M.7
Oertel, W.H.8
Olanow, C.W.9
Poewe, W.10
Rascol, O.11
Tolosa, E.12
Squillacote, D.13
Kumar, D.14
-
192
-
-
69549126673
-
Serotonin and Parkinson's disease: On movement, mood, and madness
-
Fox, S.H.; Chuang, R.; Brotchie, J.M. Serotonin and Parkinson's disease: On movement, mood, and madness. Movement Disord., 2009, 24, 1255-1266.
-
(2009)
Movement Disord.
, vol.24
, pp. 1255-1266
-
-
Fox, S.H.1
Chuang, R.2
Brotchie, J.M.3
-
193
-
-
33847757879
-
Sarizotan as a treatment for dyskinesias in Parkinson's disease: A double-blind placebocontrolled trial
-
Goetz, C.G.; Damier, P.; Hicking, C.; Laska, E.; Muller, T.; Olanow, C.W.; Rascol, O.; Russ, H. Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebocontrolled trial. Movement Disord., 2007, 22, 179-186.
-
(2007)
Movement Disord.
, vol.22
, pp. 179-186
-
-
Goetz, C.G.1
Damier, P.2
Hicking, C.3
Laska, E.4
Muller, T.5
Olanow, C.W.6
Rascol, O.7
Russ, H.8
-
194
-
-
78049251350
-
Effects of piclozotan (SUN N4057), a partial serotonin 1A receptor agonist, on motor complications induced by repeated administration of levodopa in parkinsonian rats
-
Tani, Y.; Ogata, A.; Koyama, M.; Inoue, T. Effects of piclozotan (SUN N4057), a partial serotonin 1A receptor agonist, on motor complications induced by repeated administration of levodopa in parkinsonian rats. Eur. J. Pharmacol., 2010, 649, 218-223.
-
(2010)
Eur. J. Pharmacol.
, vol.649
, pp. 218-223
-
-
Tani, Y.1
Ogata, A.2
Koyama, M.3
Inoue, T.4
-
195
-
-
51449123001
-
Non-dopaminergic treatments in development for Parkinson's disease
-
Fox, S.H.; Brotchie, J.M.; Lang, A.E. Non-dopaminergic treatments in development for Parkinson's disease. Lancet Neurol., 2008, 7, 927-938.
-
(2008)
Lancet Neurol.
, vol.7
, pp. 927-938
-
-
Fox, S.H.1
Brotchie, J.M.2
Lang, A.E.3
-
196
-
-
0035209620
-
International union of pharmacology XXV nomenclature and classification of adenosine receptors
-
Fredholm, B.B.; IJzerman, A.P.; Jacobson, K.A.; Klotz, K.-N.; Linden, J. International Union of Pharmacology. XXV. Nomenclature and Classification of Adenosine Receptors. Pharmacol. Rev., 2001, 53(4), 527-552.
-
(2001)
Pharmacol. Rev.
, vol.53
, Issue.4
, pp. 527-552
-
-
Fredholm, B.B.1
Ijzerman, A.P.2
Jacobson, K.A.3
Klotz, K.-N.4
Linden, J.5
-
197
-
-
79952033865
-
International union of basic and clinical pharmacology LXXXI. Nomenclature and classification of adenosine receptors-an update
-
Fredholm, B.B.; Ijzerman, A.P.; Jacobson, K.A.; Linden, J.; Mueller, C.E. International union of basic and clinical pharmacology. LXXXI. Nomenclature and classification of adenosine receptors-an update. Pharmacol. Rev., 2011, 63, 1-34.
-
(2011)
Pharmacol. Rev.
, vol.63
, pp. 1-34
-
-
Fredholm, B.B.1
Ijzerman, A.P.2
Jacobson, K.A.3
Linden, J.4
Mueller, C.E.5
-
198
-
-
79952027612
-
Recent developments in adenosine receptor ligands and their potential as novel drugs
-
Mueller, C.E.; Jacobson, K.A. Recent developments in adenosine receptor ligands and their potential as novel drugs. Biochim. Biophys. Acta, Biomembr., 2011, 1808, 1290-1308.
-
(2011)
Biochim. Biophys. Acta, Biomembr.
, vol.1808
, pp. 1290-1308
-
-
Mueller, C.E.1
Jacobson, K.A.2
-
199
-
-
14544288232
-
Therapeutic potential of adenosine A2A receptor antagonists in Parkinson's disease
-
Xu, K.; Bastia, E.; Schwarzschild, M. Therapeutic potential of adenosine A2A receptor antagonists in Parkinson's disease. Pharmacol. Ther., 2005, 105, 267-310.
-
(2005)
Pharmacol. Ther.
, vol.105
, pp. 267-310
-
-
Xu, K.1
Bastia, E.2
Schwarzschild, M.3
-
200
-
-
33750171348
-
Targeting adenosine A2A receptors in Parkinson's disease
-
Schwarzschild, M.A.; Agnati, L.; Fuxe, K.; Chen, C.-F.; Morelli, M. Targeting adenosine A2A receptors in Parkinson's disease Trends Neurosci., 2006, 29, 647-654.
-
(2006)
Trends Neurosci.
, vol.29
, pp. 647-654
-
-
Schwarzschild, M.A.1
Agnati, L.2
Fuxe, K.3
Chen, C.-F.4
Morelli, M.5
-
201
-
-
47349112609
-
Adenosine A2A receptor antagonists and Parkinson's disease: State of the art and future directions
-
Simola, N.; Morelli, M.; Pinna, A. Adenosine A2A receptor antagonists and Parkinson's disease: state of the art and future directions. Curr. Pharm. Des., 2008, 14, 1475-1489.
-
(2008)
Curr. Pharm. Des.
, vol.14
, pp. 1475-1489
-
-
Simola, N.1
Morelli, M.2
Pinna, A.3
-
202
-
-
0035195117
-
Adenosine A2A receptor antagonists: Potential therapeutic and neuroprotective effects in Parkinson's disease
-
Morelli, M.; Wardas, J. Adenosine A2A receptor antagonists: Potential therapeutic and neuroprotective effects in Parkinson's disease. Neurotoxic. Res., 2001, 3, 545-556.
-
(2001)
Neurotoxic. Res.
, vol.3
, pp. 545-556
-
-
Morelli, M.1
Wardas, J.2
-
203
-
-
0035318509
-
Oglimerization of G-protein-coupled transmitter receptors
-
Bouvier, M., Oglimerization of G-protein-coupled transmitter receptors. Nat. Rev. Neurosci., 2001, 2, 274-286.
-
(2001)
Nat Rev. Neurosci.
, vol.2
, pp. 274-286
-
-
Bouvier, M.1
-
204
-
-
48449100036
-
Detection of heteromerization of more than two proteinsby sequential BRET-FRET
-
Carriba, P.; Navarro, G.; Ciruela, F.; Ferre, S.; Casado, V.; Agnati, L.; Cortes, A.; Mallol, J.; Fuxe, K.; Canela, E.I.; Lluís, C.; Franco, R. Detection of heteromerization of more than two proteinsby sequential BRET-FRET. Nat. Methods, 2008, 5, 727-733.
-
(2008)
Nat. Methods
, vol.5
, pp. 727-733
-
-
Carriba, P.1
Navarro, G.2
Ciruela, F.3
Ferre, S.4
Casado, V.5
Agnati, L.6
Cortes, A.7
Mallol, J.8
Fuxe, K.9
Canela, E.I.10
Lluís, C.11
Franco, R.12
-
205
-
-
0037124032
-
Coaggregation, cointernalization, and codesensitization of adenosine A2A recepters and dopamine d2 receptors
-
Hillion, J.; Canals, M.; Torvinen, M.; Casado, V.; Scott, R.; Tetrasmaa, A.; Hansson, A.; Watson, S.; Olah, M.E.; Mallol, J.; Canela, E.I.; Zoli, M.; Agnati, L.F.; Ibanez, C.F.; Lluís, C.; Franco, R.; Ferre, S.; Fuxe, K. Coaggregation, Cointernalization, and Codesensitization of Adenosine A2A Recepters and Dopamine D2 Receptors. J. Biol. Chem., 2002, 277, 18091-18097.
-
(2002)
J. Biol. Chem.
, vol.277
, pp. 18091-18097
-
-
Hillion, J.1
Canals, M.2
Torvinen, M.3
Casado, V.4
Scott, R.5
Tetrasmaa, A.6
Hansson, A.7
Watson, S.8
Olah, M.E.9
Mallol, J.10
Canela, E.I.11
Zoli, M.12
Agnati, L.F.13
Ibanez, C.F.14
Lluís, C.15
Franco, R.16
Ferre, S.17
Fuxe, K.18
-
206
-
-
84858226578
-
Crosstalk within gpcr heteromers in schizophrenia and parkinson's disease: Physical or just functional
-
Guixa-Gonzalez, R.; Bruno, A.; Marti-Solano, M.; Selent, J. Crosstalk within GPCR heteromers in schizophrenia and Parkinson's disease: physical or just functional? Curr. Med. Chem., 2012, 19, 1119-1134.
-
(2012)
Curr. Med. Chem.
, vol.19
, pp. 1119-1134
-
-
Guixa-Gonzalez, R.1
Bruno, A.2
Marti-Solano, M.3
Selent, J.4
-
207
-
-
0034738134
-
Association of coffee and caffeine intake with the risk of parkinson disease
-
Ross, G.W.; Abbott, R.D.; Petrovitch, H.; Morens, D.M.; Grandinetti, A.; Tung, K.-H.; Tanner, C.M.; Masaki, K.H.; Blanchette, P.L.; Curb, J.D.; Popper, J.S.; White, L.R. Association of Coffee and Caffeine Intake With the Risk of Parkinson Disease. JAMA, 2000, 283, 2674-2679.
-
(2000)
JAMA
, vol.283
, pp. 2674-2679
-
-
Ross, G.W.1
Abbott, R.D.2
Petrovitch, H.3
Morens, D.M.4
Grandinetti, A.5
Tung, K.-H.6
Tanner, C.M.7
Masaki, K.H.8
Blanchette, P.L.9
Curb, J.D.10
Popper, J.S.11
White, L.R.12
-
208
-
-
0342591409
-
-
May 23
-
Caulkett, P.W.R.; Jones, G.; Collis, M.G.; Poucher, S.M. Preparation of (amino)heteroaryl[1,2,4]triazolo[1,5-a]triazines and related compounds as adenosine A2 receptor antagonists EP 459702, May 23, 1991.
-
(1991)
Preparation of (amino)heteroaryl[1,2,4]triazolo[1,5-a]triazines and Related Compounds As Adenosine A2 Receptor Antagonists EP 459702
-
-
Caulkett, P.W.R.1
Jones, G.2
Collis, M.G.3
Poucher, S.M.4
-
209
-
-
84880762491
-
Synthesis, molecular structure, NMR spectroscopic and computational analysis of a selective adenosine A2A antagonist, ZM 241385
-
Jörg, M.; Agostino, M.; Yuriev, E.; Mak, F.S.; Miller, N.D.; White, J.; Scammells, P.J.; Capuano, B. Synthesis, molecular structure, NMR spectroscopic and computational analysis of a selective adenosine A2A antagonist, ZM 241385. Struct. Chem., 2013, 24, 1241-1251.
-
(2013)
Struct. Chem.
, vol.24
, pp. 1241-1251
-
-
Jörg, M.1
Agostino, M.2
Yuriev, E.3
Mak, F.S.4
Miller, N.D.5
White, J.6
Scammells, P.J.7
Capuano, B.8
-
210
-
-
84877584576
-
Novel adenosine A2A receptor ligands: A synthetic, functional and computational investigation of selected literature adenosine A2A receptor antagonists for extending into extracellular space
-
Jörg, M.; Shonberg, J.; Mak, F.S.; Miller, N.D.; Yuriev, E.; Scammells, P.J.; Capuano, B. Novel adenosine A2A receptor ligands: A synthetic, functional and computational investigation of selected literature adenosine A2A receptor antagonists for extending into extracellular space. Bioorg. Med. Chem. Lett., 2013, 23, 3427-3433.
-
(2013)
Bioorg. Med. Chem. Lett.
, vol.23
, pp. 3427-3433
-
-
Jörg, M.1
Shonberg, J.2
Mak, F.S.3
Miller, N.D.4
Yuriev, E.5
Scammells, P.J.6
Capuano, B.7
-
211
-
-
84871806184
-
Stabilised G protein-coupled receptors in structure-based drug design: A case study with adenosine A2A receptor
-
Andrews, S.P.; Tehan, B. Stabilised G protein-coupled receptors in structure-based drug design: a case study with adenosine A2A receptor. Med. Chem. Commun., 2013, 4, 52-67.
-
(2013)
Med. Chem. Commun.
, vol.4
, pp. 52-67
-
-
Andrews, S.P.1
Tehan, B.2
-
212
-
-
56749103466
-
The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist
-
(5905)
-
Jaakola, V.-P.; Griffith, M.T.; Hanson, M.A.; Cherezov, V.; Chien, E.Y.T.; Lane, J.R.; IJzerman, A.P.; Stevens, R.C. The 2.6 Angstrom Crystal Structure of a Human A2A Adenosine Receptor Bound to an Antagonist. Science, 2008, 322(5905), 1211-1217.
-
(2008)
Science
, vol.322
, pp. 1211-1217
-
-
Jaakola, V.-P.1
Griffith, M.T.2
Hanson, M.A.3
Cherezov, V.4
Chien, E.Y.T.5
Lane, J.R.6
Ijzerman, A.P.7
Stevens, R.C.8
-
213
-
-
79960156006
-
Biophysical mapping of the adenosine A2A receptor
-
Zhukov, A.; Andrews, S.P.; Errey, J.C.; Robertson, N.; Tehan, B.; Mason, J.S.; Marshall, F.H.; Weir, M.; Congreve, M. Biophysical Mapping of the Adenosine A2A Receptor. J. Med. Chem., 2011, 54, 4312-4323.
-
(2011)
J. Med. Chem.
, vol.54
, pp. 4312-4323
-
-
Zhukov, A.1
Andrews, S.P.2
Errey, J.C.3
Robertson, N.4
Tehan, B.5
Mason, J.S.6
Marshall, F.H.7
Weir, M.8
Congreve, M.9
-
214
-
-
79960181417
-
Structure of the adenosine A2a receptor in complex with ZM241385 and the xanthines xac and caffeine
-
Doré, Andrew S.; Robertson, N.; Errey, James C.; Ng, I.; Hollenstein, K.; Tehan, B.; Hurrell, E.; Bennett, K.; Congreve, M.; Magnani, F.; Tate, Christopher G.; Weir, M.; Marshall, Fiona H. Structure of the Adenosine A2A Receptor in Complex with ZM241385 and the Xanthines XAC and Caffeine. Structure, 2011, 19(9), 1283-1293.
-
(2011)
Structure
, vol.19
, Issue.9
, pp. 1283-1293
-
-
Doré, A.S.1
Robertson, N.2
Errey, J.C.3
Ng, I.4
Hollenstein, K.5
Tehan, B.6
Hurrell, E.7
Bennett, K.8
Congreve, M.9
Magnani, F.10
Tate Christopher, G.11
Weir, M.12
Marshall, F.H.13
-
215
-
-
80155142267
-
Future treatments for parkinson's disease: Surfing the pd pipeline
-
Hauser, R.A. Future Treatments for Parkinson's Disease: Surfing the PD Pipeline. Int. J. Neurosci., 2011, 121, 53-62.
-
(2011)
Int. J. Neurosci.
, vol.121
, pp. 53-62
-
-
Hauser, R.A.1
-
216
-
-
84878952850
-
Istradefylline: First global approval
-
Dungo, R.; Deeks, E.D. Istradefylline: first global approval. Drugs, 2013, 73, 875-882.
-
(2013)
Drugs
, vol.73
, pp. 875-882
-
-
Dungo, R.1
Deeks, E.D.2
-
217
-
-
0033038568
-
Comparison of CGS 15943, ZM 241385 and SCH 58261 as antagonists at human adenosine receptors
-
Ongini, E.; Dionisotti, S.; Gessi, S.; Irenius, E.; Fredholm, B.B. Comparison of CGS 15943, ZM 241385 and SCH 58261 as antagonists at human adenosine receptors. N.-S. Arch. Pharmacol., 1999, 359, 7-10.
-
(1999)
N.-S. Arch. Pharmacol.
, vol.359
, pp. 7-10
-
-
Ongini, E.1
Dionisotti, S.2
Gessi, S.3
Irenius, E.4
Fredholm, B.B.5
-
218
-
-
33846903864
-
Potent, selective, and orally active adenosine A2A receptor antagonists: Arylpiperazine derivatives of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines
-
Neustadt, B.R.; Hao, J.; Lindo, N.; Greenlee, W.J.; Stamford, A.W.; Tulshian, D.; Ongini, E.; Hunter, J.; Monopoli, A.; Bertorelli, R.; Foster, C.; Arik, L.; Lachowicz, J.; Ng, K.; Feng, K.-I. Potent, selective, and orally active adenosine A2A receptor antagonists: Arylpiperazine derivatives of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines. Bioorg. Med. Chem. Lett., 2007, 17, 1376-1380.
-
(2007)
Bioorg. Med. Chem. Lett.
, vol.17
, pp. 1376-1380
-
-
Neustadt, B.R.1
Hao, J.2
Lindo, N.3
Greenlee, W.J.4
Stamford, A.W.5
Tulshian, D.6
Ongini, E.7
Hunter, J.8
Monopoli, A.9
Bertorelli, R.10
Foster, C.11
Arik, L.12
Lachowicz, J.13
Ng, K.14
Feng, K.-I.15
-
220
-
-
27444442267
-
2-n-butyl-9-methyl-8-[1,2,3]triazol-2-yl-9h-purin-6-ylamine and analogues as A2A adenosine receptor antagonists design, synthesis, and pharmacological characterization
-
Minetti, P.; Tinti, M.O.; Carminati, P.; Castorina, M.; Di, C.M.A.; Di, S.S.; Gallo, G.; Ghirardi, O.; Giorgi, F.; Giorgi, L.; Piersanti, G.; Bartoccini, F.; Tarzia, G. 2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6- ylamine and Analogues as A2A Adenosine Receptor Antagonists. Design, Synthesis, and Pharmacological Characterization. J. Med. Chem., 2005, 48, 6887-6896.
-
(2005)
J. Med. Chem.
, vol.48
, pp. 6887-6896
-
-
Minetti, P.1
Tinti, M.O.2
Carminati, P.3
Castorina, M.4
Di, C.M.A.5
Di, S.S.6
Gallo, G.7
Ghirardi, O.8
Giorgi, F.9
Giorgi, L.10
Piersanti, G.11
Bartoccini, F.12
Tarzia, G.13
-
221
-
-
0042141599
-
A2A antagonist prevents dopamine agonist-induced motor complicationsin animal models of Parkinson's disease
-
Bibbiani, F.; Oh, J.D.; Petzer, J.P.; Castagnoli, N.; Chen, J.F.; Schwarzschild, M.A.; Chase, T.N. A2A antagonist prevents dopamine agonist-induced motor complicationsin animal models of Parkinson's disease. Exp. Neurol., 2003, 184, 285-294.
-
(2003)
Exp. Neurol.
, vol.184
, pp. 285-294
-
-
Bibbiani, F.1
Oh, J.D.2
Petzer, J.P.3
Castagnoli, N.4
Chen, J.F.5
Schwarzschild, M.A.6
Chase, T.N.7
-
222
-
-
34249034952
-
Characterization of the antiparkinsonian effects of the new adenosine A2A receptor antagonist ST1535: Acute and subchronic studies in rats Eur
-
Tronci, E.; Simola, N.; Borsini, F.; Schintu, N.; Frau, L.; Carminati, P.; Morelli, M. Characterization of the antiparkinsonian effects of the new adenosine A2A receptor antagonist ST1535: Acute and subchronic studies in rats Eur. J. Pharmacol., 2007, 566, 94-102.
-
(2007)
J. Pharmacol.
, vol.566
, pp. 94-102
-
-
Tronci, E.1
Simola, N.2
Borsini, F.3
Schintu, N.4
Frau, L.5
Carminati, P.6
Morelli, M.7
-
223
-
-
0022902748
-
Opioid agonist and antagonist bivalent ligands the relationship between spacer length and selectivity at multiple opioid receptors
-
Portoghese, P.S.; Larson, D.L.; Sayre, L.M.; Yim, C.B.; Ronsisvalle, G.; Tam, S.W.; Talemori, A.E. Opioid agonist and antagonist bivalent ligands. The relationship between spacer length and selectivity at multiple opioid receptors J. Med. Chem., 1986, 29, 1855-1861.
-
(1986)
J. Med. Chem.
, vol.29
, pp. 1855-1861
-
-
Portoghese, P.S.1
Larson, D.L.2
Sayre, L.M.3
Yim, C.B.4
Ronsisvalle, G.5
Tam, S.W.6
Talemori, A.E.7
-
224
-
-
0032474283
-
Dimers of 5HT1 ligands preferentially bind to 5HT1B/1D receptor subtypes Bioorg
-
Perez, M.; Jordan-Lebrun, C.; Pauwels, P.J.; Pallard, I.; Halazy, S. Dimers of 5HT1 ligands preferentially bind to 5HT1B/1D receptor subtypes Bioorg. Med. Chem. Lett., 1998, 8, 1407-1412.
-
(1998)
Med. Chem. Lett.
, vol.8
, pp. 1407-1412
-
-
Perez, M.1
Jordan-Lebrun, C.2
Pauwels, P.J.3
Pallard, I.4
Halazy, S.5
-
225
-
-
10544224535
-
Serotonin dimers: Application of the bivalent ligand approach to the design of new potent and selective 5-ht1b/1d agonists j
-
Halazy, S.; Perez, M.; Fourrier, C.; Pallard, I.; Pauwels, P.J.; Palmier, C.; John, G.W.; Valentin, J.P.; Bonnafous, R.; Martinez, J. Serotonin Dimers: Application of the Bivalent Ligand Approach to the Design of New Potent and Selective 5-HT1B/1D Agonists J. Med. Chem., 1996, 39, 4920-4927.
-
(1996)
Med. Chem.
, vol.39
, pp. 4920-4927
-
-
Halazy, S.1
Perez, M.2
Fourrier, C.3
Pallard, I.4
Pauwels, P.J.5
Palmier, C.6
John, G.W.7
Valentin, J.P.8
Bonnafous, R.9
Martinez, J.10
-
226
-
-
34548487956
-
Synthesis of specific bivalent probes that functionally interact with 5-HT4 receptor dimers j
-
Russo, O.; Berthouze, M.; Giner, M.; Soulier, J.L.; Rivail, L.; Sicsic, S.; Lezoulac'h, F.; Jockers, R.; Berque-Bestel, I. Synthesis of Specific Bivalent Probes That Functionally Interact with 5-HT4 Receptor Dimers J. Med. Chem., 2007, 50, 4482-4492.
-
(2007)
Med. Chem.
, vol.50
, pp. 4482-4492
-
-
Russo, O.1
Berthouze, M.2
Giner, M.3
Soulier, J.L.4
Rivail, L.5
Sicsic, S.6
Lezoulac'H, F.7
Jockers, R.8
Berque-Bestel, I.9
-
227
-
-
3242794178
-
From magic bullets to designed multiple ligands
-
Morphy, R.; Kay, C.; Rankovic, Z. From magic bullets to designed multiple ligands. Drug Discov. Today, 2004, 9, 641-651.
-
(2004)
Drug Discov. Today
, vol.9
, pp. 641-651
-
-
Morphy, R.1
Kay, C.2
Rankovic, Z.3
-
228
-
-
2542625998
-
A bivalent ligand (KDN-21) reveals spinal - and - opioid receptors are organized as heterodimers that give rise to -1 and -2 phenotypes
-
Bhushan, R.G.; Sharma, S.K.; Xie, Z.; Daniels, D.J.; Portoghese, P.S. A bivalent ligand (KDN-21) reveals spinal - and - opioid receptors are organized as heterodimers that give rise to -1 and -2 phenotypes. selective targeting of -heterodimers J. Med. Chem., 2004, 47, 2969-2972.
-
(2004)
Selective Targeting of -Heterodimers J. Med. Chem.
, vol.47
, pp. 2969-2972
-
-
Bhushan, R.G.1
Sharma, S.K.2
Xie, Z.3
Daniels, D.J.4
Portoghese, P.S.5
-
229
-
-
0022251438
-
Stereostructure-activity relationship of opioid agonist and antagonist bivalent ligands Evidence for bridging between vicinal opioid receptors
-
Portoghese, P.S.; Larson, D.L.; Yim, C.B.; Sayre, L.M.; Ronsisvalle, G.; Lipkowski, A.W.; Takemori, A.E.; Rice, K.C.; Tam, S.W. Stereostructure-activity relationship of opioid agonist and antagonist bivalent ligands. Evidence for bridging between vicinal opioid receptors J. Med. Chem., 1985, 28, 1140-1141.
-
(1985)
J. Med. Chem.
, vol.28
, pp. 1140-1141
-
-
Portoghese, P.S.1
Larson, D.L.2
Yim, C.B.3
Sayre, L.M.4
Ronsisvalle, G.5
Lipkowski, A.W.6
Takemori, A.E.7
Rice, K.C.8
Tam, S.W.9
-
230
-
-
0032531947
-
Spanning binding sites on allosteric proteins with polymer-linked ligand dimers
-
Kramer, R.H.; Karpen, J.W. Spanning binding sites on allosteric proteins with polymer-linked ligand dimers Nature, 1998, 395, 710-713.
-
(1998)
Nature
, vol.395
, pp. 710-713
-
-
Kramer, R.H.1
Karpen, J.W.2
-
231
-
-
70349192980
-
Adenosine A2A receptor-antagonist/dopamine d2 receptor-agonist bivalent ligands as pharmacological tools to detect A2AD2 receptor heteromers
-
Soriano, A.; Ventura, R.; Molero, A.; Hoen, R.; Casadó, V.; Cortés, A.; Fanelli, F.; Albericio, F.; Lluís, C.; Franco, R.; Royo, M. Adenosine A2A Receptor-Antagonist/Dopamine D2 Receptor-Agonist Bivalent Ligands as Pharmacological Tools to Detect A2AD2 Receptor Heteromers. J. Med. Chem., 2009, 52, 5590-5602.
-
(2009)
J. Med. Chem.
, vol.52
, pp. 5590-5602
-
-
Soriano, A.1
Ventura, R.2
Molero, A.3
Hoen, R.4
Casadó, V.5
Cortés, A.6
Fanelli, F.7
Albericio, F.8
Lluís, C.9
Franco, R.10
Royo, M.11
-
232
-
-
15444364860
-
A bivalent ligand (KDAN-18) containing -antagonist and -agonist pharmacophores bridges -2 and -1 opioid receptor phenotypes
-
Daniels, D.J.; Kulkarni, A.; Xie, Z.; Bhushan, R.G.; Portoghese, P.S. A Bivalent Ligand (KDAN-18) Containing -Antagonist and -Agonist Pharmacophores Bridges -2 and -1 Opioid Receptor Phenotypes. J. Med. Chem., 2005, 48, 1713-1716.
-
(2005)
J. Med. Chem.
, vol.48
, pp. 1713-1716
-
-
Daniels, D.J.1
Kulkarni, A.2
Xie, Z.3
Bhushan, R.G.4
Portoghese, P.S.5
-
233
-
-
44949250688
-
Blood-brain barrier permeability considerations for CNS-targeted compound library design
-
Hitchcock, S.A. Blood-brain barrier permeability considerations for CNS-targeted compound library design. Curr. Opin. Chem. Biol., 2008, 12, 318-323.
-
(2008)
Curr. Opin. Chem. Biol.
, vol.12
, pp. 318-323
-
-
Hitchcock, S.A.1
-
234
-
-
84858045382
-
A novel conjugated agent between dopamine and an A2A adenosine receptor antagonist as a potential anti-parkinson multitarget approach
-
Dalpiaz, A.; Cacciari, B.; Vicentini, C.B.; Bortolotti, F.; Spalluto, G.; Federico, S.; Pavan, B.; Vincenzi, F.; Borea, P.A.; Varani, K. A Novel Conjugated Agent between Dopamine and an A2A Adenosine Receptor Antagonist as a Potential Anti-Parkinson Multitarget Approach. Mol. Pharmaceutics, 2012, 9, 591-604.
-
(2012)
Mol. Pharmaceutics
, vol.9
, pp. 591-604
-
-
Dalpiaz, A.1
Cacciari, B.2
Vicentini, C.B.3
Bortolotti, F.4
Spalluto, G.5
Federico, S.6
Pavan, B.7
Vincenzi, F.8
Borea, P.A.9
Varani, K.10
-
235
-
-
79851495268
-
Synthesis and biological evaluation of a new series of 1,2,4-triazolo[1,5-A]-1,3,5-triazines as human A2A adenosine receptor antagonists with improved water solubility
-
Federico, S.; Paoletta, S.; Cheong, S.L.; Pastorin, G.; Cacciari, B.; Stragliotto, S.; Klotz, K.N.; Siegel, J.; Gao, Z.-G.; Jacobson, K.A.; Moro, S.; Spalluto, G. Synthesis and Biological Evaluation of a New Series of 1,2,4-Triazolo[1,5-a]-1,3,5-triazines as Human A2A Adenosine Receptor Antagonists with Improved Water Solubility. J. Med. Chem., 2011, 54, 877-889.
-
(2011)
J. Med. Chem.
, vol.54
, pp. 877-889
-
-
Federico, S.1
Paoletta, S.2
Cheong, S.L.3
Pastorin, G.4
Cacciari, B.5
Stragliotto, S.6
Klotz, K.N.7
Siegel, J.8
Gao, Z.-G.9
Jacobson, K.A.10
Moro, S.11
Spalluto, G.12
-
236
-
-
0037375621
-
Inhibition of monoamine oxidase B by selective adenosine A2A receptor antagonists
-
Petzer, J.P.; Steyn, S.; Castagnoli, K.P.; Chen, J.-F.; Schwarzschild, M.A.; Van, d.S.C.J.; Castagnoli, N. Inhibition of monoamine oxidase B by selective adenosine A2A receptor antagonists. Bioorg. Med. Chem., 2003, 11, 1299-1310.
-
(2003)
Bioorg. Med. Chem.
, vol.11
, pp. 1299-1310
-
-
Petzer, J.P.1
Steyn, S.2
Castagnoli, K.P.3
Chen, J.-F.4
Schwarzschild, M.A.5
Van, D.S.C.J.6
Castagnoli, N.7
-
237
-
-
84873937179
-
Synthesis of (E)-8-(3-chlorostyryl)caffeine analogues leading to 9-deazaxanthine derivatives as dual A2A antagonists/mao-b inhibitors
-
Rivara, S.; Piersanti, G.; Bartoccini, F.; Diamantini, G.; Pala, D.; Riccioni, T.; Stasi, M.A.; Cabri, W.; Borsini, F.; Mor, M.; Tarzia, G.; Minetti, P. Synthesis of (E)-8-(3-Chlorostyryl)caffeine Analogues Leading to 9-Deazaxanthine Derivatives as Dual A2A Antagonists/MAO-B Inhibitors. J. Med. Chem., 2013, 56, 1247-1261.
-
(2013)
J. Med. Chem.
, vol.56
, pp. 1247-1261
-
-
Rivara, S.1
Piersanti, G.2
Bartoccini, F.3
Diamantini, G.4
Pala, D.5
Riccioni, T.6
Stasi, M.A.7
Cabri, W.8
Borsini, F.9
Mor, M.10
Tarzia, G.11
Minetti, P.12
-
238
-
-
51449101712
-
Dual inhibition of monoamine oxidase B and antagonism of the adenosine A2A receptor by (E,E)-8-(4-phenylbutadien-1-yl)caffeine analogues
-
Pretorius, J.; Malan, S.F.; Castagnoli, N.; Bergh, J.J.; Petzer, J.P. Dual inhibition of monoamine oxidase B and antagonism of the adenosine A2A receptor by (E,E)-8-(4-phenylbutadien-1-yl)caffeine analogues. Bioorg. Med. Chem., 2008, 16, 8676-8684.
-
(2008)
Bioorg. Med. Chem.
, vol.16
, pp. 8676-8684
-
-
Pretorius, J.1
Malan, S.F.2
Castagnoli, N.3
Bergh, J.J.4
Petzer, J.P.5
-
239
-
-
84879045217
-
Dual targeting of the adenosine a2a receptors and monoamine oxidase b by 4H-3,1-benzothiazin-4-ones
-
Stößel, A.; Hinz, S.; Küppers, P.; Heer, J.; Gütschow, M.; Müller, C.E. Dual Targeting of the Adenosine A2A Receptors and Monoamine Oxidase B by 4H-3,1-Benzothiazin-4-ones. J. Med. Chem., 2013, 56, 4580-4596.
-
(2013)
J. Med. Chem.
, vol.56
, pp. 4580-4596
-
-
Stößel, A.1
Hinz, S.2
Küppers, P.3
Heer, J.4
Gütschow, M.5
Müller, C.E.6
-
240
-
-
0032609798
-
Antiparkinsonian activity of adenosine A2A antagonists in experimental models
-
Kuwana, Y.; Shiozaki, S.; Kanda, T.; Kurokawa, M.; Koga, K.; Ochi, M.; Ikeda, K.; Kase, H.; Jackson, M.J.; Smith, L.A.; Pearce, R.K.; Jenner, P.G. Antiparkinsonian activity of adenosine A2A antagonists in experimental models. Adv. Neurol., 1999, 80, 121-123.
-
(1999)
Adv. Neurol.
, vol.80
, pp. 121-123
-
-
Kuwana, Y.1
Shiozaki, S.2
Kanda, T.3
Kurokawa, M.4
Koga, K.5
Ochi, M.6
Ikeda, K.7
Kase, H.8
Jackson, M.J.9
Smith, L.A.10
Pearce, R.K.11
Jenner, P.G.12
|